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By the end of the 20th century atherosclerotic cardiovascular disease was 
expected to be eliminated due to adequate treatment of the classic 
cardiovascular risk factors, hypercholesterolemia and hypertension. 
However, nowadays cardiovascular disease is expected to be the main 
cause of morbidity and mortality owing to increasing prevalence in 
developing countries and rising incidence of obesity and related diseases 
like diabetes, hypertension, dyslipidemia and chronic kidney disease in the 
western world.1 Especially in patients with type 2 diabetes and end-stage 
renal disease (ESRD) cardiovascular disease is a prominent cause of 
mortality.2-4 In particular in the latter patient group therapies proven to be 
successful in the general population have thus far been disappointing.5-7 
This underscores the importance of unravelling the atherosclerotic process, 
in particular in renal patients, to ultimately discover novel targets for 
prevention and treatment. 
 
Atherosclerotic lesions 
The atherosclerotic process is characterized by arterial lesions that progress 
from endothelial dysfunction to an initial fatty streak towards an unstable, 
vulnerable plaque in the arterial vessel wall. The process responsible for this 
is called ‘the response to injury hypothesis’ described by Ross and 
Glomsed.8 This process is initiated by activation and dysfunction of 
endothelial cells. Both environmental factors, like hyperlipidemia and genetic 
factors play a crucial role in this process (gene-environment interaction). The 
endothelial dysfunction together with expression of adhesion molecules and 
release of cytokines and chemokines increases vascular permeability and 
allows monocytes and T-cells and other inflammatory cells to migrate into 
the subendothelial space.4, 9-12  
The fatty streak is an early atherosclerotic lesion caused by the local uptake 
of lipids by endothelial cells, particularly at sites of hemodynamic strain. In 
the intima, these lipoproteins are modified into oxidized lipoproteins, which 
cause a local inflammatory response again leading to platelet and leucocyte 
adhesion. Monocytes invading the fatty streak differentiate into 
macrophages that take up excess lipids, a process that eventually causes 
them to differentiate into foam cells. Accumulation of additional inflammatory 
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cells leads to atherosclerotic plaque formation. The more advanced stable 
plaque (atheroma) consists of a thick fibrous cap with high collagen and 
smooth muscle cell content and a lipid core that in turn is constituted by 
foam cells, debris and lipid droplets. The presence of an intact advanced 
plaque may lead to a stenotic obstruction of the blood vessel and hereby 
leading to angina. Moreover, mechanisms that largely remain unknown but 
are clearly related to macrophage infiltration may render a stable plaque 
unstable and prone to rupture. Plaque rupture results in exposure of the 
plaque’s prothrombotic core content and leads to massive local blood 
coagulation and formation of a thrombus. Such thrombosis may lead to 
obstruction of blood vessels and hereby to infarction.4, 11 
 
Inflammation, end stage renal disease, diabetes and atherosclerosis 
It is now widely recognized that inflammation plays a crucial role in the 
development of atherosclerosis.4, 13, 14 This chronic inflammatory condition is, 
at least in part, responsible for the elevated overall and cardiovascular 
mortality seen in type 2 diabetes.3, 4, 15 Also in ESRD a persistent 
inflammatory state is a well know risk factor for morbidity and mortality, both 
cardiovascular and non-cardiovascular.16-19 
The immune response seen in atherosclerosis can be separated into an 
innate immune response involving expression of adhesion molecules, 
chemokine release and monocyte/ macrophage and natural killer (NK) T cell 
recruitment and an adaptive immune response involving B cells and antigen 
specific T cells (Figure 1 and 2).1, 20-23 The B and T cells respond to antigens 
presented by antigen presenting cells (dendritic cells, B cells and 
macrophages). Numerous candidate antigens have emerged, both microbial 
and self-antigens, but their contribution during atherogenesis remains 
unclear.20 Different T cell subclasses are involved.24 Both CD4+ and CD8+ T 
cells are found in human lesions but CD4+ cells dominate.20, 23, 24 CD4+ T 
cells can differentiate into different subsets, like T helper 1 (Th1) cells, T 
helper 2 (Th2) cells, T helper 17 (Th17) cells and regulatory T cells. The 
principal cytokine of Th1 cells is IFN- and is produced by the majority of all 
T cells in atherosclerotic plaques. Th1 cell activation also leads to TNF-α 
secretion. IFN- and TNF-α are thought to play a pro-inflammatory, pro-
atherosclerotic role.20, 21, 24, 25 Th2 cells and the cytokines IL-4, IL-5 and IL-10 
play, at least in part an anti-inflammatory, anti-atherogenic role.20, 24, 25  
        
Figure 1: Monocyte recruitment 
through the activated endothelium 
and differentiation into macrophages. 
These macrophages release 
cytokines, chemokines and other 
inflammatory cells leading to 
inflammation and tissue damage 
(reprint with permission, N Eng J Med 
2005;352-1685-95). 
Figure 2: Antigens presented by 
macrophages and dendritic cells trigger 
activation of antigen specific T cells. 
Most of the activated T cells produce 
Th1 cytokines leading to inflammation. 
Regulatory T cells modulate this 
process  (reprint with permission,         
N Eng J Med 2005;352-1685-95). 
 
As with CD4+ T cells, CD8+ T cells can differentiate to T cytotoxic (Tc)1 or 
Tc2-cell subsets, secreting predominantly Th1 or Th2 cytokines 
respectively.26 The role of IL-17, which is produced by Th17 cells, in 
atherosclerosis is not yet clear.25, 27 Regulatory T cells, especially regulatory 
T cells type 1 are thought to play a central role in counteracting disease 
initiation and progression.20, 28 The effects of B cells and their antibodies 
seem to depend on their antigen specificity.20, 29 
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In this process of inflammation and atherosclerosis different chemokines 
play an important role.12, 30 Chemokines can be classified into four major 
categories (C, CC, CXC and CX3C) depending on the arrangement of their 
N-terminal cysteine residues. Chemokines bind to and activate specific G 
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protein coupled receptors, chemokine receptors, present on the surface of 
leucocytes, dendritic cells, endothelial cells and smooth muscle cells 
resulting in specific cellular functions such as migration (chemotaxis), firm 
adhesion to the vessel wall and/or transmigration through the vascular 
endothelium. The involvement of chemokines and chemokine receptors 
suggests that these ‘players’ may provide novel targets for therapeutic 
intervention in atherosclerosis-related diseases. From the chemokine family 
CC chemokines have been widely implicated in atherosclerosis and also CC 
chemokine blockade has been found to reduce atherosclerosis in ApoE 
knockout mice.31 In particular there is evidence for important and distinct 




One of the chemokine receptors with a possible role in atherosclerosis is the 
CC-chemokine receptor 5 (CCR5). CCR5 is expressed on T cells, 
monocytes/macrophages, smooth muscle cells and endothelial cells.33, 34 
These cells are involved in the chronic inflammatory state that is observed in 
insulin resistance, type 2 diabetes, atherosclerosis and uremia.4, 10, 15, 17 
Several genetic polymorphisms have been described for CCR5. The 
CCR5∆32 genetic variant is located on the chromosome 3p21 and consists 
of a 32-basepair deletion in the open reading frame. It effectively results in 
functional CCR5 deficiency by absence of CCR5 membrane expression.35 In 
the Caucasian population approximately 15% is heterozygous for the 
CCR5∆32 allele and 1-2% homozygous.36 The CCR5∆32 effectively results 
in functional CCR5 deficiency by absence of CCR5 membrane expression in 
homozygotes and reduced membrane expression in heterozygotes.35   
CCR5 is particularly interesting given the availability of an approved 
pharmacological antagonist, providing opportunities for intervention, and 
because of the existence of the aforementioned genetic variant CCR5∆32 
leading to CCR5 deficiency. The latter allows the study of “knock-down” of 
the human CCR5 gene on chronic inflammatory diseases like 
atherosclerosis in renal patients. Data on HIV epidemiology demonstrate 
that genetic deficiency of the CCR5 is associated with resistance to HIV 
infection, as CCR5 modulates virus entry.37, 38 In line with a functional, 
protective effect against HIV infection, association studies showed that 
15 
 
CCR5∆32 is associated with better outcome in patients with a high risk for 
atherosclerotic cardiovascular disease and renal transplant recipients,39-42 
albeit not invariably so.43-45 Modulation of the inflammatory response was 
suggested to be involved in the effect of CCR5∆32 on prognosis in cardio-
renal conditions. In animal studies using mouse models the role of both 
pharmacological CCR5 receptor antagonism and genetic deletion of CCR5 
in the atherosclerotic, inflammatory response has been verified.46-55 
However, owing to differences in atherosclerotic disease between human 
and mouse models care must be taken to in extrapolating these results to 
the clinic. Studies in human cells and tissue are critical in substantiating the 
role of CCR5 in disease development. Different human studies show that 
CCR5 is present in human atherosclerotic plaque.31, 56 The mechanism by 
which CCR5 and CCR5 deficiency contribute to chronic inflammation and 
atherosclerosis are believed to be due to its effects on immune cell migration 
and response.12, 57 Notably, in mice CCR5 deficiency was associated with a 
reduction in Th1-type immune response.46, 49 Besides this, in animal models 
CCR5 deficiency modulates monocyte recruitment in atherosclerotic lesions 
and is associated with improved plaque stability.11, 12, 48   
Taken together, CCR5 is a plausible candidate for modulation of the process 
of atherosclerosis, in particular atherosclerosis in the context of a chronic 
pro-inflammatory state. The studies in this thesis therefore focus on CCR5 
as a possible target for intervention in the chronic inflammatory process of 
atherosclerotic disease in ESRD and type 2 diabetes. To this purpose, we 
studied the epidemiological and functional consequences of the CCR5∆32 
polymorphism in ERSD and type 2 diabetes.   
 
Outline of the thesis 
In chapter 2 we tested the hypothesis that CCR5∆32 is associated with 
mortality in patients with type 2 diabetes. To this purpose we investigated 
whether the presence or absence of CCR532 is associated with overall 
and/or cardiovascular mortality in a longitudinal follow-up cohort of type 2 
diabetic patients. Unfortunately, the possible interference with the 
inflammatory state could not be tested as data on inflammation were not 




An elevated serum level of C-reactive protein (CRP) is an established 
marker of systemic inflammation.58, 59 In dialysis patients CRP has been 
strongly associated with overall and cardiovascular mortality, supporting the 
impact of inflammation in particular in this high-risk group.17, 60-63 In this 
process the CCR5 receptor might well contribute to atherogenesis through 
the binding of its ligands, which in turn mediate the recruitment of 
inflammatory cells to the endothelium. The presence of a dysfunctional 
receptor could be a rate-limiting factor in the increased mortality associated 
with systemic inflammation in dialysis patients. In chapter 3 we therefore 
tested the hypothesis that the CCR532 genotype might alter the previously 
observed association of elevated CRP with mortality in ESRD. Thus, we 
investigated whether the CCR532 genetic variant modifies the effect of 
CRP on mortality in a Dutch dialysis cohort (NECOSAD). For independent 
confirmation we analysed the corresponding associations in a Swedish 
cohort of ESRD patients. 
Of the vast family of cytokines, TNF-α, IL-6 and IL-10 seem to play a major 
role in the development of Th1/Th2 imbalance, leading to increased 
(cardiovascular) complications and worse outcome in patients with ESRD.64 
In atherosclerosis in mice, CCR5 deficiency is associated with a more 
pronounced Th2 type immune response and less TNF-α and INF-γ 
production hereby counteracting the Th1 directed Th1/Th2 disequilibrium of 
atherosclerotic inflammation.46, 48, 49, 53 In chapter 4 we hypothesize that the 
previously observed protection from CRP related (cardiovascular) mortality 
in CCR5∆32 carriers (chapter 3) is (in part) due to blunting of the pro-
inflammatory immune response in carriers of the deletion. We tested this in a 
cohort of incident dialysis patients in who levels of CRP, TNF-α, IL-6 and IL-
10 were assessed and related to their CCR5∆32 genotype. In chapter 5 this 
possible explanation for the protection by the CCR5∆32 genotype due to a 
more Th2 type directed immune response was further tested by studying 
differences in cytokine level after stimulation of peripheral mononuclear cells 
(PBMCs) and by studying the distribution of Th1, Th2 and Th17 directed 
circulating CD4+ and CD8+ T cells, based on their intracellular cytokine 
profile and regulatory T cells after stimulation in patients with ESRD with and 




Development of novel pharmacological approaches followed by randomized 
clinical trials is expensive and time consuming, providing an immense 
obstacle to the development and introduction of innovative approaches in 
patient care.65 Therefore, alternative strategies are urgently needed to 
facilitate the multi-faceted process from drug development to introduction in 
clinical practice. Observational studies using genetic variants might provide 
such a strategy. Data obtained through genetic association studies could be 
considered a type of natural, lifelong, clinical trial, with genetically different 
groups being randomized at conception, hereby limiting confounding. This 
approach is known as Mendelian randomization.66-68 We found that 
CCR5∆32, leading to CCR5 deficiency was associated with protection 
against mortality in patients with ESRD with elevated CRP as a sign of 
systemic inflammation.69 These data suggest that intervention targeting the 
CCR5 may have the potential to improve prognosis in ESRD.70 In line with 
the above, genetic association data on long term outcome in patients with 
CCR5∆32 versus those with the wild-type genotype can be considered as a 
virtual long term randomized intervention study on pharmacological blockade 
of the CCR5 receptor, thus providing a rapid and cheap simulation set-up for 
a real-life clinical trial. In chapter 6 we use this concept to estimate the 
potential cost-effectiveness of CCR5Δ32 screening and pharmacological 
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Aim of this study was to test whether the genetic variant CCR5∆32 in the 
CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is 
associated with mortality in type 2 diabetes patients. 
We examined the effect of presence or absence of the CCR5∆32 on overall 
and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project 
Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient 
cohort.  
We studied 756 patients with a mean duration of follow-up of 5.4 ( 1.4) 
years. 194 patients died during follow up of which 83 were cardiovascular 
deaths. 144 subjects (19%) carried the CCR5∆32 deletion. CCR5∆32 
carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40-0.96; p=0.03) for 
all-cause mortality and 0.63 (95%CI: 0.33-1.19; p=0.16) for cardiovascular 
mortality. 
The presence of CCR5∆32 is associated with better survival in type 2 
diabetes patients. These data suggest that it is worthwhile to explore the 





Chemokines and their receptors have a central role in leucocyte trafficking, 
and are involved in the pathophysiology of various inflammatory disorders.1, 2 
Genetic variability in the chemokine cascades could therefore potentially 
modify inflammatory processes. For the CC-chemokine receptor 5 (CCR5) 
several polymorphisms have been described. Among these, the CCR5∆32 
genetic variant, consisting of a 32-basepair deletion in the open reading 
frame effectively results in functional CCR5 deficiency by absence of CCR5 
membrane expression. Heterozygous subjects express a lower amount of 
functional receptors compared to wild-type homozygotes.3 The 
pathophysiological significance of the CCR5∆32 genetic variant is 
demonstrated by its association with resistance to HIV infection, where 
CCR5 modulates virus entry.4, 5 
CCR5 is expressed on T cells, macrophages, smooth muscle cells and 
endothelial cells.6, 7 These cells are involved in the chronic inflammatory 
state present in insulin resistance, type 2 diabetes, atherosclerosis and 
uremia.2, 8-10 In line with its protective effect in HIV, CCR5∆32 has also been 
shown to be associated with better outcome in patients with a high risk for 
atherosclerotic cardiovascular disease, dialysis patients and renal transplant 
recipients, probably by modulation of the inflammatory response in these 
conditions.11-15  
Type 2 diabetes is characterized by a particularly elevated overall and 
cardiovascular mortality, attributed at least partly to a generalized 
inflammatory condition.8, 16 This elicits the hypothesis that CCR5∆32 could 
be associated with mortality risk in type 2 diabetes as well. To test this 
hypothesis, in the current study we investigated whether the presence or 
absence of CCR532 is associated with overall and/or cardiovascular 
mortality in a longitudinal follow-up cohort of type 2 diabetic patients.  
 
Patients and Methods 
Patients 
This study is part of the Zwolle Outpatient Diabetes project Integrating 
Available Care (ZODIAC). In this project, general practitioners (GP) receive 
support by diabetic specialists for the implementation of the Dutch national 
guidelines in care of type 2 diabetic patients.  Patients were recruited from 
the eastern part of the Netherlands. In a part of this project all patients with 
type 2 diabetes, exclusively treated by their GP are followed annually. These 
patients (n=1149) are part of the present study. Eligibility criteria were: type 
2 diabetes, as defined by the national guidelines of the Dutch college of 
general practitioners (based on the 1997 American Diabetes Association 
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criteria) treated by a general practitioner. All patients gave informed consent 
before being included. The study was approved by the local medical ethics 
committee. Patients were included between January 1998 and December 
1999. Details were described previously.17 For the current analyses data 
were used from patients who gave permission for DNA analyses (n=798). 
Patients were followed until date of death or date of censoring, i.e. 
withdrawal from the study or end of the follow-up period (December 2004).  
Demographic and clinical data 
The following data were collected: age, gender, smoking habit, medication 
use, systolic and diastolic standing, office blood pressure after 5 minute rest 
(Tycos sphygmomanometer; Welch Allyn B.V., Delft, the Netherlands), 
medical history and co-morbidity, body mass index (BMI) and diabetes 
duration. A blood sample and a urine sample were obtained. Serum lipids, 
serum creatinine and urine albumine/kreatinine ratio were determined by 
routine assays (Roche/ Hitachi modular analyzer; Roche diagnostics, Laval, 
QC, Canada). HbA1C was determined by high performance liquid 
chromatography (Primus CLC-385; Primus Corp., Kansas City, MO, USA). 
Creatinine clerance was calculated using the MDRD formula.18 Patients with 
a history of angina pectoris, myocardial infarction, heart failure, stroke or 
claudication at time of inclusion were defined as having cardiovascular 
disease. Dates of death were determined by reviewing patient records or 
were reported by the general practitioner and were checked at the Central 
Bureau of Statistics. The cause of death was obtained by linking the number 
of the death certificate to the primary cause of death as coded by a 
physician from the Central Bureau of Statistics. Cardiovascular causes of 
death were coded according to the International Classification of Diseases 
(ICD), 9th revision. Death due to ischemic coronary heart disease, heart 
failure, and cerebrovascular disease were coded as cardiovascular death. 
DNA preparation and Polymerase Chain Reaction analysis 
The CCR5 gene is located on chromosome 3p21. In the assay, genotypes 
were determined by discrimination during the polymerase chain reaction 
(PCR) with two allele-specific probes (PE Biosystems, Foster city, CA, USA). 
Each assay requires two unlabeled primers (Life Technologies, Foster city, 
CA, USA). The PCR was accomplished by using Taqman universal master 
mix (PE Biosystems, Foster city, CA, USA). A detailed description was 
published previously.19 Patients were divided in 2 groups according to their 
CCR5 genotype namely those homozygous for the major allele (non-
carriers) and those with 1 or 2 deletion alleles (carriers). Patients with one or 
two deletion alleles were grouped together, as it has been demonstrated that 
presence of one minor allele is sufficient to compromise CCR5 function.3 
Moreover, the number of individuals homozygous for the minor allele was 




Hardy-Weinberg equilibrium was calculated using the gene-counting 
method. Differences between groups were tested with the chi-square test for 
dichotomous and categorical variables and one-way ANOVA for continuous 
variables. Survival of overall and cardiovascular mortality was investigated 
using univariate and multivariate Cox’s propotional-hazard analyses. A 
primary multivariate analysis included age and sex as possible confounders. 
In further multivariate analyses, additional adjustment was performed for 
variables with significant difference between the two genotype groups. 
Finally, additional adjustment was performed for variables with more than 
10% difference between the two groups. Cumulative hazards were 
calculated to display the survival model graphically. All statistical analyses 
were performed with SPSS statistical software (version 14.0; SPSS, 
Chicago, IL, USA). A p-value of 0.05 was assumed to indicate statistical 
significance for all analyses. 
 
Results 
A total of 798 patients were included. In 42 patients (5.3%) the CCR5 
genotype could not be determined. These patients showed similar baseline 
characteristics to the genotyped patients (data not shown). Further statistical 
analyses were performed on the 756 patients who were genotyped for 
CCR5. 
The CCR5 ins32 (+)/del32 (∆) genotype was distributed as follows: 613 +/+ 
(81.1%), 137 +/∆ (18.1%) and 6 ∆/∆ (0.8%). The genotype frequency did not 
deviate significantly from Hardy-Weinberg equilibrium (P=0.58). As stated in 
the methods section we combined carriers of the CCR532 genetic variant 
into a single carrier genotype group of 143 individuals (18.9%). 
Table 1 lists the baseline characteristics of the population stratified by CCR5 
genotype. The patient characteristics for the different genotype groups were 
largely similar, except systolic and diastolic blood pressure and HDL 
cholesterol level. Carriers of the ∆32 polymorphism had a higher systolic and 
diastolic blood pressure and a higher HDL cholesterol level. Also the use of 
lipid lowering drugs was different between both groups, with less use of lipid 
lowering drugs in carriers. 
The mean follow-up duration was 5.4  1.4 with a maximum of 6.8 years. In 
46 (38 (6.2%) non-carriers and 8 (5.6%) carriers) of the 756 patients no 




Table 1: Baseline characteristics of the ZODIAC cohort 
 
 CCR5 +/+ 
(n=613) 
CCR5 +/Δ and ∆/∆ 
(n=143) 
p 
Male sex (%) 42.4 38.5 0.39 
Age (years) 68 ± 11 68 ± 10 0.44 
Smoking (%)             





Never 51.3 54.4 
Previously 29.8 31.6 
 
0.41 
CVD (%) 36.2 28.7 0.10 
DM duration (years) 7.2 ± 8.0 6.2 ± 6.1 0.17 
SBP (mmHg) 153 ± 25 159 ± 27 0.01 
DBP (mmHg) 84 ± 12 86 ± 11 0.04 
BMI (kg/m²) 28.8 28.7 0.80 
TC (mmol/l) 5.6 ± 1.1 5.8 ± 1.1 0.10 
HDL-c (mmol/l) 1.16 ± 0.33 1.23 ± 0.34 0.03 
HbA1C (mmol/l) 7.4 ± 1.2 7.3 ± 1.3 0.19 
eGFR (ml/min) 75.9 ± 17.7 76.2 ± 16.8 0.89 
Alb/creat ratio > 2.5 
males,        
> 3.5 females 
36.8 40.2 0.48 
ADT (%)                              





Only oral drugs 73.1 69.9 
Only insulin 12.8 16.2 




AHT (%) 43.4 39.7 0.43 
LLD (%) 11.3 5.1 0.03 
Aspirin (%) 12.0 9.6 0.43 
 
CVD, history of cardiovascular disease; ADT, anti-diabetic treatment; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; BMI, body mass index; TC, total 
cholesterol; HDL-c, HDL-cholesterol; eGFR, estimated GFR by MDRD formula; AHT, 
anti-hypertensive treatment; LLD, lipid-lowering drugs. Data are presented as 
percentage or mean (SD). 
 
A total of 194 (25.7%) patients died during the follow-up period at an 
average of 4.8% per year: 167 (27.2%) in the non-carrier group and 27 
(18.8%) in the carrier group. None of the six patients homozygous for the 
deletion allele died during follow-up. From the total number of deaths 83 
(42.7%) were of cardiovascular cause (72 (11.7%) in the non-carrier and 11 
(7.7%) in the carrier group). In 44 patients the cause of death was classified 
as due to malignancy, in 15 patients cause of death was classified as due to 
respiratory causes, in 5 patients cause of death was classified as trauma, 
and in 47 patients death was due to other causes. These causes of death 
were distributed equally between the two genotype groups.  
Table 2: Hazard ratios, 95%CI and p-values for all-cause and cardiovascular 
mortality by CCR5∆32 genotype 
 








CCR5 +/+  1 1 




0.04 0.62 (0.40-0.96) 
 
0.03 













CCR5 +/+  1 1 








Non-carriers (CCR5 +/+) were used as reference in Cox regression analysis. In the 
crude model no further adjustments were made. In the adjusted model, age and sex 





Figure 1: Cumulative hazard (%) for all-cause mortality in DM II patients stratified by 
presence of the CCR5∆32 minor allele. Non-carriers (-CCR5∆32) show a higher 





In multivariate Cox regression analyses (adjusted for age and sex), the 
hazard ratios of CCR5∆32 carriers compared to non-carriers were 0.62 (95% 
CI: 0.40-0.96, p=0.03) for all-cause mortality and 0.63 (95% CI: 0.33-1.19, 
p=0.16) for cardiovascular mortality (table 2). For mortality due to ischemic 
heart disease (n=31) alone, the adjusted hazard ratio was 0.29 (95% CI: 
0.07-1.21; p=0.09). The adjusted hazard ratio for non-cardiovascular 
mortality was 0.61 (95% CI: 0.34-1.10, p=0.10). Further adjustment for 
factors that were significantly different at baseline between the two genotype 
groups (blood pressure, HDL cholesterol and lipid lowering medication) did 
not alter the results. In un additional multivariate model, adjustment for 
factors that were not significantly different but had a more than 10% 
difference between the two genotype groups at baseline (CVD, diabetic 
duration and anti-diabetic treatment) did not materially affect the results 
(data not shown). Figure 1 illustrates the survival model for all-cause 
mortality depending on CCR5∆32 genotype. 
 
Discussion 
In this longitudinal follow-up in type 2 diabetes patients the presence of the 
CCR532, leading to CCR5 deficiency, was associated with lower all-cause 
mortality. Hazard ratios for cardiovascular and non-cardiovascular mortality 
and especially mortality due to ischemic heart disease were also lower in 
carriers of the CCR532 variant but these differences did not reach 
statistical significance. These data are the first to demonstrate the 
association of CCR532 with mortality in patients with diabetes type 2.  
These data are in line with the impact of the CCR532 in several other 
populations. Data in HIV infection, where CCR5 modulates virus entry, 
provided the first evidence for pathophysiological impact of the CCR5 
deficiency that is conferred by CCR532 as carriers showed resistance 
against HIV infection.5 Causality was supported by a recent case report on a 
patient with acute myeloid leukaemia and HIV infection, who remained 
without viral rebound after transplantation with stem cells from a donor 
homozygous for CCR532.4 Case-control studies in cardiovascular disease 
demonstrated that CCR532 is associated with a reduced incidence of 
myocardial infarction at younger age in men and with protection against 
coronary heart disease.12, 14 In a nested case-control study within the 
Nurses’ Health Study a possible association was found between reduced 
incidence of early onset coronary heart disease in women.13 Indeed, in 
animal studies, it has been suggested that CCR5 and its ligands play a role 
in the pathogenesis and progression of vascular disease.20-22 From the 
function of CCR5 it would be logical to assume that CCR532 modulates 
inflammatory responses. In line with this assumption, CCR532 is 
associated with protection against rheumatoid arthritis and with better 
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outcome in renal transplantation, a condition characterized by persistent 
inflammation.11, 23 Recently we demonstrated gene-environment interaction 
between CCR532 and inflammatory status in two independent cohorts of 
dialysis patients, where CCR532 abolishes the well-established association 
between elevated CRP and mortality.15 Taken together these studies 
suggest that CCR532 modulates outcome in various inflammatory-driven 
disease processes. Our current data extend these findings to type 2 
diabetes. 
Our study was not designed to address the mechanisms underlying the 
impact of CCR532 on mortality, but several inferences can be made. Most 
likely a dysfunctional CCR5 could be related to lower over-all mortality by 
modulating inflammatory responses. Interestingly, a Polish study reported 
over expression of CCR5 on circulating blood mononuclear cells in type 2 
diabetic patients compared to healthy controls.24 In addition, high plasma 
levels of the CCR5 ligand CCL5 were associated with increased cardiac 
mortality.25 Another study by Boger et al. suggested that up regulation of 
CCR5 could lead to accelerated atherosclerosis in type 2 diabetes mellitus 
patients on hemodialysis.26 Also other CCR5 polymorphisms have been 
implicated in the development of diabetic complications.27, 28 Together these 
findings support involvement of CCR5-mediated inflammatory processes in 
the outcome of diabetes. Thus, the CCR5 deficiency resulting from the 
CCR532 variant could explain why carriers had a better survival in our 
study.  
What could be the implications of our findings? First, they could contribute to 
risk stratification. Moreover, they support the rationale for pharmacological 
blockade of the CCR5 as a preventive strategy. This idea is supported by 
animal data showing that the CCR5 antagonist Met-RANTES reduced 
progression of atherosclerosis in hypercholesterolemic mice and with 
reduced neo-intimal plaque area and macrophage infiltration in apoE 
deficient mice.21, 29 Finally, treatment with TAK-799, a CCR5 chemokine 
receptor antagonist, reduced lesion development in a collar-induced carotid 
artery atherosclerosis model.30 In humans, pharmacological blockade of the 
CCR5 is also feasible, as recently this strategy has been introduced for 
treatment of HIV infection, but so far no experience is available in other 
conditions.31  
Our study has several limitations. We excluded a number of patients for 
which CCR5 genotype was not determined that could potentially introduce a 
selection-bias. However, it is highly unlikely that this sporadic technical 
failure would distribute unequally among patients, as patient characteristics 
were similar in genotyped versus non-genotyped subjects. Another limitation 
is that causes of death could have been misdocumented and hereby may 
have biased the result concerning cardiovascular and non-cardiovascular 
mortality. However, this could not have influenced our main outcome, ie. all-
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cause mortality. The incidence of mortality in our study population is 
comparable to that reported in literature, suggesting that in terms of 
mortality, our study population resembles a ordinarily type 2 diabetes 
population.32 Population stratification is a form of confounding that may 
occur in genetic association studies when a distinct population comprises 
subgroups with different genetic background. Unfortunately, data on ethnicity 
were not recorded. However in the region of the Netherlands were the study 
was performed the vast majority of inhabitants is of Caucasian origin. 
Besides this the genotype did not deviate from Hardy Weinberg equilibrium. 
So, this form of confounding is not likely to play an important role. To 
overcome bias through selection and population stratification replication of 
our findings in an independent population would have been helpful. Whereas 
this is a single center study, and no formal replication is provided, our data 
are in line with those in other populations, thus supporting its credibility.   
In genetic association studies adjustment for other factors than age and sex 
could potentially introduce interference in the causal pathway and thereby 
bias through overadjustment.33 For this reason we reported unadjusted 
hazard ratios and hazard ratios adjusted for age and sex in the manuscript. 
Even adjustment for the factors that were at baseline significantly different or 
showed a more than 10% difference between the 2 genotype groups did not 
materially affect our conclusions. Moreover, as CCR532 carriers survived 
longer despite higher blood pressure it could be hypothesized that carriers 
are more resistant to adverse events related to elevated blood pressure. 
Similarly, less lipid lowering treatment in CCR5∆32 carriers apparently did 
not adversely affect their survival. Finally, we only studied a single 
polymorphism. The observed effect does not necessarily causally implicate 
this particular polymorphism, but could be due to another variant in linkage 
disequilibrium with the studied deletion. This is a point that deserves further 
investigation. However, our efforts as reported in the present study were not 
toward in-depth characterization of the gene locus, but rather to investigate 
whether the reported impact in the literature of CCR532, leading to CCR5 
deficiency, was also present in a diabetic population. 
CCR5 deficiency due to the presence of the CCR5∆32 genotype, is 
associated with improved survival in type 2 diabetes. These data are in line 
with previous data and support the pathophysiological impact of the CCR5. 
They suggest that pharmacological blockade of the CCR5, which has 
recently become feasible in humans, could have the potential to improve 
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A genetic polymorphism of the CC-chemokine receptor 5 (CCR5∆32) leads 
to CCR5 deficiency. We hypothesized that CCR5∆32 modulates 
inflammation driven mortality in end stage renal disease (ESRD) patients 
and therefore studied the interaction between CCR5 genotype and CRP 
levels.  
We included 603 patients from the NEtherlands COoperative Study on the 
Adequacy of Dialysis (NECOSAD) cohort, a multicenter prospective follow-
up study in incident dialysis patients. In 413 patients (68%) the CCR5 
genotype and hsCRP levels were available. Patients were followed for a 
median of 3.75 years.  
A total of 170 patients died during 5 years of follow-up (87 cardiovascular). 
By combining the presence or absence of the CCR5∆32 polymorphism with 
hsCRP levels effect modification was studied. This showed that compared to 
the reference group, ie. patients with the wild type genotype and 
hsCRP<10mg/l (n=225), patients carrying the deletion allele with 
hsCRP<10mg/l (n=55) had the same survival (HR: 0.90 (95%CI: 0.54-1.50; 
p=0.69). Patients carrying the wild type genotype with hsCRP>10mg/l 
(n=108) had an increased mortality (HR: 1.82 (95%CI: 1.29-2.58; p<0.01). 
However, in carriers of the deletion allele with hsCRP>10mg/l (n=25) 
survival was the same as in the reference group (HR: 1.39 (95%CI: 0.73-
2.62; p=0.32)). This effect was even more pronounced for cardiovascular 
mortality. This finding was replicated in an independent Swedish cohort of 
302 ESRD patients.  
The CCR5∆32 polymorphism attenuates the adverse effects of an 




Cardiovascular disease (CVD) is a prominent cause of mortality in end-stage 
renal disease (ESRD) patients.1  A persistent inflammatory state has been 
recognized a risk factor in this respect. An established marker of systemic 
inflammation is an elevated serum level of C-reactive protein (CRP).2, 3 
Although CRP has been strongly associated with overall and cardiovascular 
mortality in dialysis patients, recent evidence suggests that CRP itself does 
not have an atherogenic potential.4-9  
The inflammatory process in atherosclerosis is characterized by infiltration of 
monocytes and T-lymphocytes in the vascular wall in response to 
chemokines. Different studies suggest that the chemokines CCL5/RANTES, 
CCL3/macrophage inflammatory protein (MIP)-1α and CCL4/MIP-1β and 
their receptor CC-chemokine receptor 5 (CCR5) play a role in the 
pathogenesis of atherosclerosis.10-14 CCR5 is expressed on the principal cell 
types implicated in atherogenesis.15-18  
In states of inflammation the CCR5 receptor could contribute to 
atherogenesis through the binding of its ligands, which in turn mediate the 
recruitment of inflammatory cells to the endothelium. Interestingly, patients 
with a dysfunctional CCR5 due to the gene polymorphism CCR5 deletion 32 
(CCR532), a 32-basepair deletion in the open reading frame leading to 
premature termination of the protein and sequestration in the endoplasmic 
reticulum, have an improved prognosis in atherosclerotic diseases.19-23 Thus, 
CCR532 could be a rate-limiting factor in the increased mortality rate 
associated with systemic inflammation.  
We therefore hypothesized that the CCR532 polymorphism might alter the 
previously observed association of elevated CRP with mortality in ESRD. To 
test this hypothesis we investigated whether the CCR532 polymorphism 
modifies the effect of CRP on mortality in a Dutch dialysis cohort 
(NECOSAD). For independent confirmation, we analysed the corresponding 




This study is part of the NEtherlands COoperative Study on the Adequacy of 
Dialysis (NECOSAD). This is a multicenter prospective follow-up study in 
which new ESRD patients from 38 Dutch dialysis centers are included at 
start of chronic dialysis treatment. All patients gave informed consent and all 
local medical ethics committees gave their approval.  
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Eligibility criteria were: 18 years and older and no previous renal 
replacement therapy. For the current analyses, data were used from patients 
included between July 1998 and December 2001 in 23 centers that 
approved of DNA analysis and had a follow-up of at least 3 months. An 
additional criterion was that the response rate was more than 50% for DNA 
analyses of patients in these centers. 
Demographic and clinical data 
The collected data included: age, gender, smoking, primary kidney disease, 
systolic and diastolic blood pressure, co-morbidity, dialysis modality and 
medication use. Blood and 24-hour urine samples were obtained at 3 
months after start of dialysis. Plasma hemoglobin, creatinine, urea, albumin 
and cholesterol levels were determined. High sensitivity CRP (hsCRP) was 
measured by means of particle-enhanced immunonephelometry using a 
standard CardioPhase hsCRP for BNII (Dade Behring Holding GmbH, 
Liederbach, Germany. Detection limit 0.1 mg/l, precision 0.1 mg/l).6 In 
addition, blood was collected for DNA analysis. Urea and creatinine were 
also analyzed in the urine sample. Renal function, expressed as glomerular 
filtration rate (GFR), was calculated as the mean of creatinine and urea 
clearance, corrected for body surface area (mL/min/1.73m²). Patients were 
followed at 3 and 6 months after start of dialysis and thereafter every 6 
months until date of death or date of censoring, i.e. transfer to a non-
participating dialysis center, withdrawal from the study or end of the follow-
up period in June 2007. Patients receiving a kidney transplant were not 
censored.  
Clinical definitions 
Primary kidney disease and causes of death were classified according to the 
codes of the European Renal Association – European Dialysis and 
Transplantation Association (ERA-EDTA).24 The following codes were 
designated as cardiovascular mortality: myocardial ischemia and infarction; 
cardiac failure/ fluid overload/ pulmonary oedema; cardiac arrest, cause 
unknown; cerebro-vascular accident; haemorrhage from ruptured vascular 
aneurysm; mesenteric infarction; hyperkalaemia; hypokalaemia; cause of 
death uncertain/ unknown. The patients were grouped in 4 classes of 
primary kidney diseases: glomerulonephritis, diabetes mellitus, renal 
vascular disease and other kidney diseases. Other kidney diseases 
consisted of patients with interstitial nephritis, polycystic kidney diseases, 
other multi-system diseases and unknown diseases.  
Patients with a history of angina pectoris, myocardial infarction, heart failure, 
ischemic stroke or claudication at time of inclusion were defined as having 




Systemic inflammation was defined as hsCRP concentration above 10mg/l. 
This cut-off point was previously used to divide patients in a group with or 
without a chronic inflammatory state.6 In ESRD patients this cut-off point for 
CRP level has been shown to be the best with regard to the prediction of 
survival.25 
CCR5 polymorphism 
The CCR5 gene is located on chromosome 3p21. The genotypes were 
determined with a PCR-based allelic discrimination assay using primers (Life 
Technologies) and allele-specific probes (PE Biosystems) as described 
previously.26 
Patients were divided in 2 groups based on their CCR532 genotype: those 
homozygous for the major allele (functional receptor) and those with 1 or 2 
deletion alleles (dysfunctional receptor). Patients homo- or heterozygous for 
the deletion-allele were clustered since the presence of one minor allele has 
already been associated with reduced receptor function 27.  
Replication 
For independent replication of the NECOSAD study results data from a 
Swedish cohort of  ESRD patients were analysed. This is a prospective 
follow-up study in patients with ESRD close to the start of renal replacement 
therapy done in Sweden. Only patients older than 18 years and younger 
than 70 years were included. Patients who were hospitalized with clinical 
signs of infection and/or acute vasculitis at time of admission were not 
included. Patients were examined and blood was collected close to start of 
dialysis treatment. A detailed description was published previously.28 
Genotype analyses were performed by PCR amplification followed by size 
separation of the resulting fragments on a 3% agarose gel and visualization 
by ethiduim bromide staining. The resulting fragments were 241 and 209 bp 
for the ins and the del allele, respectively. Patients were followed until date 
of death or date of censoring, i.e. end of the follow-up period (March 2007). 
Definitions for cardiovascular disease, cardiovascular death, systemic 
inflammation were the same as described above for the NECOSAD cohort.  
Statistics 
Hardy-Weinberg equilibrium was calculated using the gene-counting 
method. Differences  
between groups were tested with the chi-square test for dichotomous and 
categorical variables and one-way ANOVA for continuous variables. The 
main outcome measure was all-cause and cardiovascular mortality within 
five years of follow-up. The survival curves were determined with the 
Kaplan-Meier method. The log rank test was used to determine differences 
between survival curves. Unadjusted, adjusted (for gender, age at inclusion, 
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cardiovascular disease, diabetes mellitus and dialysis modality) hazard 
ratios (HRs) for all-cause, cardiovascular and non-cardiovascular mortality 
were calculated by Cox’s proportional-hazard analysis.  
In order to study the modification of the effect of hsCRP on mortality by the 
CCR5 genotype according to Rothmans approach of studying effect 
modification (i.e. additive interaction) 29 between hsCRP and CCR5 
genotype, a new variable with four categories was defined: CCR5 ins/ins 
with low hsCRP (<10mg/l), CCR5 ins/ins with high hsCRP (>10mg/l), 
CCR532 with low hsCRP (<10mg/l) and CCR532 with high hsCRP level 
(>10mg/l).  
This association was also examined for hsCRP level as a continuous 
variable by studying its effect on mortality within the two separate CCR5 
genotype groups. Because of the skewed distribution, hsCRP data were first 
log-transformed.  
Finally, to increase the number of patients in the different categories and 
hereby power, the 2 cohorts were combined. For the combined cohort Cox’s 
proportional-hazard analysis was performed also. 
All statistical analyses were performed with SPSS statistical software 
(version 14.0; SPSS, Chicago, IL). 
 
Results 
A total of 603 patients were included in the present analysis. In 413 patients 
(68%) the CCR5 genotype and hsCRP levels were available. Compared to 
the 190 patients without hsCRP and/or CCR5 data, these patients were 
slightly older (59.7 vs 57.1 (p=0.05)) and included more HD patients (67% 
vs. 52% (P<0.01)). Comorbidities such as diabetes mellitus did not differ in 
both patients groups (35% vs. 30% (p=1.19), and 25% vs. 20% (p=0.11), 
respectively). No differences were found in serum albumin (35.7 vs. 36.3 g/l 
(p=0.25)). However, a better survival was observed for the 413 patients with 
both hsCRP and CCR5 data with a median of 1370 days (3.75 years) (710-
1826 days) of follow-up, and a mortality rate of 122 per 1000 person years 
within 5 years of follow-up, compared to a median of 1006 days of follow-up 
and a mortality rate of 147 per 1000 person years within 5 years of follow up 
for the 190 patients without hsCRP and/or CCR5 data. Further statistical 
analyses were performed on the 413 patients.  
The CCR5 ins32/del32 polymorphism was distributed as follows: ins/ins: 333 
(80.6%); ins/del: 73 (17.7%) and del/del: 7 (1.7%). The genotype distribution 
did not deviate significantly from Hardy-Weinberg equilibrium (p=0.21). 
Baseline characteristics are shown in the first column of Table 1. The patient 
characteristics for the different genotype groups were similar at the start of 
dialysis, except antihypertensive medication use. Patients homo- or 
heterozygous for the deletion allele used more antihypertensive medications 
(p=0.01). The median CRP levels in the two genotype groups were as 
follows: in the CCR5 ins/ins group: 4.7 mg/l (1.8-13.4) and in the CCR5 del 
group: 6.9 mg/l (2.4-14.1) (p=0.22). 
 








Gender: male 253 (61.3) 185 (61.3)  
Age (year)  62 (50-71) 55 (44-64)  








Primary kidney disease 
   Diabetes mellitus 
  Glomerulonephritis 
   Renal vascular 
disease 

















Polycystic kidney disease 
Other 
Cardiovascular disease 144 (34.9) 99 (32.8)  
Diabetes mellitus 105 (25.4) 88 (29.1)  
Smoking 
   Never 
   Former 






DBP (mmHg) 83 (12.8) 88 (13.2)  
SBP (mmHg)  150 (25.4) 151 (23.8)  
Antihypertensive medication 356 (86.2)   
Lipid lowering medication 121 (29.3)   
hsCRP (mg/l)   







Cholesterol (mmol/l) 5.0 (1.3) 5.3 (1.5)  
Albumin (g/l)  32.5 (6.9) 33.2 (6.1)  
Hemoglobin (g/dl) 11.0 (1.4) 10.4 (1.4)  
GFR (ml/min) 4.2 (3.1) 6.6 (2.3)  














Data are presented as number (percentage), median (25, 75 percentile), mean (SD). DBP: 
diastolic blood pressure; SBP: systolic blood pressure; GFR: glomerular filtration rate. 
Mortality and systemic inflammation 
A total of 170 (87 (51 %) cardiovascular) patients died during follow-up of 5 
years. The mortality rate in the group with hsCRP<10mg/l was 91 per 1000 
person years as opposed to 207 per 1000 person years in the group with 
hsCRP>10mg/l. Kaplan-Meier survival analysis showed a statistically 
significant difference in all-cause, cardiovascular and non-cardiovascular 
mortality for the two hsCRP level groups; those with hsCRP>10mg/l had the 
worst survival (log rank: p<0.01). These univariate findings were confirmed 
by Cox regression analysis (adjusted HR for patients with hsCRP<10mg/l 
compared to hsCPR>10mg/l for all-cause mortality: 1.78 (95%CI: 1.31-2.42; 
p<0.01), for cardiovascular mortality: 1.70 (95%CI: 1.10-2.63; p=0.02) and 
for non-cardiovascular mortality: 1.87 (95%CI: 1.20-2.91; p<0.01)).  
When analysed as a continuous variable the adjusted mortality risk per unit 
hsCRP increase was 1.31 (95%CI: 1.17-1.48; p<0.01) for all-cause mortality, 
1.24 (95%CI: 1.04-1.46; p=0.01) for cardiovascular mortality and 1.41 
(95%CI: 1.18-1.67; p<0.01) for non-cardiovascular mortality. 
Mortality and systemic inflammation and CCR5 polymorphism interaction 
Of the 170 patients who died within 5 years of FU, 140 patients were non-
carriers of the CCR5Δ32 polymorphism (42% of all non-carriers), and 30 
patients were carriers of the polymorphism (38% of carriers). 
 
 
Figure 1: Kaplan-Meier overall survival curve for patients in the NECOSAD cohort 
according to CCR5 genotype combined with or without elevated hsCRP (mg/l) levels 
(log rank: p<0.001) 
47 
 
The Kaplan Meier survival curve (Figure 1) shows that patients with 
hsCRP>10mg/l and not carrying a deletion allele had the worst survival (log 
rank: p<0.01). In Table 2 the HRs for all-cause mortality are presented. In 
the NECOSAD cohort non-carriers of the deletion allele with hsCRP>10mg/l 
had an increased all-cause mortality risk compared to non-carriers with 
hsCRP<10mg/l. Patients in the group with hsCRP>10mg/l, carrying the 
deletion allele showed a much less elevated HR for all-cause mortality. This 
effect was even more pronounced for cardiovascular mortality (Table 2). For 
non-cardiovascular mortality the protective effect of the deletion allele in 
patients with an elevated hsCRP was less pronounced (Table 2). 
 
Table 2: Mortality rate per 1000 person years, hazard ratio (HR) (95%CI) and p-
values for all-cause, cardiovascular and non-cardiovascular mortality in the 
NECOSAD cohort and hazard ratio (HR) (95%CI) and p-values for all-cause mortality 
in the Swedish cohort. Adjusted for gender, age at inclusion, cardiovascular disease, 
diabetes and dialysis modality.  
 
NECOSAD 
CCR5 ins/ins & 
hsCRP<10mg/l 
(n=225) 









All-cause mortality     
Mortality rate 91 228 90 133 
Crude HR 1 2.55 (1.83-3.56) 1.00 (0.60-1.65) 1.48 (0.79-2.79) 
p  <0.01 0.99 0.22 
Adjusted HR 1 1.82 (1.29-2.58) 0.90 (0.54-1.50) 1.39 (0.73-2.62) 
p  <0.01 0.69 0.32 
Cardiovascular mortality     
Mortality rate 47 112 52 60 
Crude HR 1 2.50 (1.56-4.00) 1.11 (0.57-2.17) 1.30 (0.51-3.31) 
p  <0.01 0.76 0.58 
Adjusted HR 1 1.85 (1.13-3.01) 1.05 (0.53-2.07) 1.25 (0.49-3.17) 
p  0.01 0.89 0.64 
Non-cardiovascular 
mortality 
    
Mortality rate 44 116 38 72 
Crude HR 1 2.60 (1.62-4.19) 0.88 (0.41-1.88) 1.67 (0.71-3.97) 
p  <0.01 0.73 0.24 
Adjusted HR 1 1.82 (1.12-2.97) 0.76 (0.35-1.65) 1.52 (0.64-3.63) 













    
Crude HR 1 2.44 (1.50-3.99) 1.50 (0.72-3.15) 1.50 (0.66-3.40) 
p  <0.01 0.28 0.33 
Adjusted HR 1 1.67 (1.01-2.77) 1.95 (0.91-4.19) 0.94 (0.41-2.17) 
p  0.05 0.09 0.89 
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Table 3: Hazard ratio (HR) (95%CI) and p-values for all-cause, cardiovascular and 
non-cardiovascular mortality per unit hsCRP increase in the NECOSAD cohort and 
hazard ratio (HR) (95%CI) and p-values for all-cause mortality per unit hsCRP 
increase in the Swedish cohort. Adjusted for gender, age at inclusion, cardiovascular 


















CCR5 ins/ins CCR532 
All-cause mortality   
Crude HR 1.52 (1.34-1.71) 1.31 (0.93-1.84) 
P <0.01 0.13 
Adjusted HR 1.34 (1.18-1.52) 1.32 (0.89-1.97) 
P <0.01 0.17 
Cardiovascular mortality   
Crude HR 1.47 (1.24-1.75) 1.05 (0.68-1.61) 
p <0.01 0.83 
Adjusted HR 1.30 (1.08-1.55) 1.02 (0.61-1.68) 
p <0.01 0.95 
Non-cardiovascular mortality   
Crude HR 1.56 (1.31-1.86) 1.79 (1.02-3.14) 
p <0.01 0.04 
Adjusted HR 1.39 (1.16-1.66) 2.37 (1.16-4.86) 







Crude HR 1.40 (1.17-1.66) 1.18 (0.82-1.69)  
p <0.01 0.36 
Adjusted HR 1.18 (0.98-1.43) 0.73 (0.46-1.15)  
p 0.08 0.17 
 
In Table 3, the HRs for all-cause, cardiovascular and non-cardiovascular 
mortality for hsCRP level as a continuous variable for the 2 genotype groups 
are presented: hsCRP levels are associated with mortality in patients with 
the CCR5 ins/ins genotype and not in patients carrying a deletion allele, for 
cardiovascular mortality the results are more pronounced. For non-
cardiovascular mortality in both CCR5 genotype groups there was a 
significant increase in mortality risk per unit hsCRP increase.  
Limiting the analysis to patients with hsCRP level <50mg/l to exclude 
patients who could have had an acute infection showed the same HRs for 
overall and cardiovascular mortality. The HRs for non-cardiovascular 
mortality for the group with hsCRP>10mg/l, carrying the deletion allele 





Also, limiting the analysis to Caucasian patients resulted in comparable HRs 
(data not shown). 
By taking the median hsCRP level as cut-off point instead of using a cut off 
hsCRP level of 10mg/l to divide patients into two groups (with or without a 
systemic inflammation respectively), yielded similar results. Also, extending 
the follow-up to more than 5 years did not significantly change the results; 
neither did further adjusting for primary kidney disease, smoking, blood 
pressure and medication use (data not shown).  
Independent replication 
The population used for confirmation consisted of 302 ESRD patients 
characterized for CCR5 genotype and hsCRP level. Baseline characteristics 
are given in the second column of Table 1. There were no differences in 
baseline characteristics between CCR532 carriers and non-carriers. The 
causes of primary kidney disease differed between the NECOSAD and the 
Swedish cohort. Also, compared to the NECOSAD study population, the 
Swedish cohort was by inclusion criteria significantly younger and a lower 
proportion of patients started on hemodialysis. Whereas mean diastolic 
blood pressure, cholesterol levels and GFR were higher, the hemoglobin 
level was lower. The median follow-up was 1457 days (3.99 years) (712-
1826). The CCR532 genotype distribution did not deviate significantly from 
Hardy-Weinberg equilibrium (p=0.22) and the allele frequencies did not differ 
from the NECOSAD cohort (p=0.96). During 5 years of follow-up 80 patients 
died (57 cardiovascular): 64 (26%) patients without the CCR532 
polymorphism and 16 (29%) of the patients carrying the CCR532 
polymorphism. In accordance with the NECOSAD cohort, in the Swedish 
cohort non-carriers of the deletion allele with an elevated hsCRP level had 
an increased mortality rate (Table 2). Similarly, carriers of the deletion allele 
without and with an elevated hsCRP showed a lower effect estimate in 
survival. For cardiovascular mortality the HRs with CCR5 ins/ins & 
hsCRP<10 as reference were as follows; CCR5 ins/ins & hsCRP>10: 2.55 
(95%CI: 1.44-4.51; p<0.01), adjusted 1.69 (95%CI: 0.94-3.05; p=0.08); 
CCR532 & hsCRP<10: 1.17 (95%CI: 0.44-3.06; p=0.76), adjusted 1.73 
(95%CI: 0.64-4.68; p=0.28); CCR532 & hsCRP>10: 1.50 (95%CI: 0.57-
3.95; p=0.41), adjusted 0.98 (95%CI: 0.37-2.61; p=0.96). For non-
cardiovascular mortality there were no statistically significant differences 
between the four groups. 
In Table 3 the HRs for all-cause mortality for hsCRP level as a continuous 
variable for the 2 genotype groups are presented. For cardiovascular 
mortality the unadjusted and adjusted risks were respectively 1.43 (95%CI: 
1.17-1.76; p<0.01) and 1.24 (95%CI: 1.00-1.55; p=0.05) in the CCR5 ins/ins 
genotype group and respectively 1.20 (95%CI: 0.76-1.89; p=0.45) and 0.55 
(95%CI: 0.27-1.11; p=0.09) in the CCR532 genotype group. 
 Table 4: Hazard ratio (HR) (95%CI) and p-values for all-cause, cardiovascular and 
non-cardiovascular mortality in the combined cohort. Adjusted for gender, age at 
inclusion, cardiovascular disease, diabetes and dialysis modality 
 
 
NECOSAD + SWEDISH 
CCR5 ins/ins & 
hsCRP<10mg/l 
(n=392) 









All-cause mortality     
Crude HR 1 2.46 (1.87-3.25) 1.16 (0.77-1.76) 1.42 (0.86-2.34) 
p  <0.01 0.49 0.17 
Adjusted HR 1 1.73 (1.31-2.30) 1.09 (0.72-1.66) 1.23 (0.74-2.02) 
p  <0.01 0.69 0.42 
Cardiovascular mortality     
Crude HR 1 2.48 (1.72-3.56) 1.14 (0.66-1.98) 1.36 (0.70-2.65) 
p  <0.01 0.63 0.37 
Adjusted HR 1 1.76 (1.21-2.54) 1.16 (0.67-2.03) 1.15 (0.59-2.25) 
p  <0.01 0.59 0.68 
Non-cardiovascular mortality     
Crude HR 1 2.45 (1.60-3.74) 1.18 (0.63-2.23) 1.50 (0.71-3.18) 
p  <0.01 0.61 0.29 
Adjusted HR 1 1.70 (1.10-2.62) 1.03 (0.54-1.95) 1.31 (0.62-2.79) 
p  0.02 0.94 0.48 
 
Combining the Swedish cohort with the NECOSAD cohort gave comparable 
results (with smaller confidence intervals) as initially found in the NECOSAD 





Our prospective study of Dutch incident dialysis patients suggest that 
mortality in ESRD associated with elevated serum hsCRP concentrations is 
modulated by the CCR532 polymorphism. Elevated hsCRP was 
significantly associated with decreased survival in patients who were 
homozygous for the major allele and thus had a functional receptor. 
Interestingly, even though elevated hsCRP conferred an increased hazard 
for mortality in carriers of the deletion allele, this was a third of the 
magnitude observed in non-carriers and not significant. For cardiovascular 
mortality this suggested protective effect of a deletion allele was even more 
pronounced. For all-cause mortality, this finding was replicated in an 
independent Swedish cohort of ESRD patients. HRs for cardiovascular 
mortality showed the same trend, although not statistically significant. Also 
when analysed on a continuous scale hsCRP levels were associated with 
(cardiovascular) mortality in patients with the CCR5 ins/ins genotype and not 
in patients carrying a deletion allele. These results suggest that CCR5 
deficiency (implicated by one or two copies of a non-functional CCR5 gene) 
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attenuates the adverse effects of a persistent inflammatory state that may 
lead to mortality in ESRD patients. Considering the importance of the 
inflammatory state for prognosis and the current developments in 
pharmacotherapy this finding may have considerable potential clinical 
implications.  
Blocking CCR5 has been proposed as a novel therapeutic approach for 
cardiovascular conditions by interfering with systemic inflammation. This 
concept is supported by an animal study by Veillard et al. in which treatment 
of hypercholesterolemic mice with the CCR5 antagonist Met-RANTES 
reduced progression of atherosclerosis.30 Moreover, Schober et al. 
demonstrated that treatment of apoE deficient mice with Met-RANTES 
reduced neo-intimal plaque area and macrophage infiltration.31 Finally, 
treatment with TAK-799, a CCR5 chemokine receptor antagonist, reduced 
lesion development in a collar-induced carotid artery atherosclerosis 
model.32 
To our knowledge, this is the first study investigating the interaction between 
CCR5 genotype, elevated (hs)CRP levels and (cardiovascular) mortality in 
dialysis patients. In line with our data, studies in other populations generally 
have shown an association of CCR532 with a favourable cardiovascular 
outcome, albeit not invariably so.33 In males the presence of CCR532 is 
associated with reduced incidence of myocardial infarction at a younger 
age.19 Another study suggested that the CCR532 genotype protected 
against coronary heart disease.21 In the Nurses’ Health study a possible 
association between the CCR532 polymorphism and a reduced incidence 
of early onset coronary heart disease was found.20 Our data extend these 
findings in a population with a particularly high cardiovascular mortality, 
namely ESRD, showing that CCR532 attenuates the risk of mortality in 
patients with systemic inflammation as determined by a high hsCRP. 
Replication in an independent, somewhat different ESRD population 
supports the robustness of this finding. In patients without systemic 
inflammation the CCR532 had no effect on mortality risk, strongly 
suggesting that the CCR532, possibly by receptor deficiency, ameliorates 
the downstream effects of systemic inflammation. 
Our data elicit the hypothesis that CCR532 modulates inflammation-driven 
atherosclerosis. Whereas our study does not allow any conclusion on the 
underlying mechanisms of the impact of CCR532 on inflammation driven 
mortality, several inferences can be made.  Chemokines play an important 
role in the recruitment of inflammatory cells mediated through chemokine 
receptors. The presence of a dysfunctional CCR5 chemokine receptor can 
modulate inflammation. This was first described in HIV infected persons. 
Homozygous carriers of the CCR532 polymorphism were protected against 
HIV infection whereas heterozygotes showed a delayed progression to AIDS 
compared to non-carriers.34-36 As inflammation is involved in atherogenesis, 
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it has been suggested that CCR5 ligands, CCR5 and genetic variation in 
CCR5 could play a role in the pathogenesis of vascular disease.10-14, 30, 37-40 
Thus, it can be hypothesized that CCR5 deficiency in carriers of the 
CCR532 polymorphism could be beneficial during an enhanced state of 
vascular inflammation. We used elevated hsCRP levels as an indicator of 
the state of (vascular) inflammation in our population, a phenotype that was 
shown to be a predictor of CVD and mortality in dialysis patients.5, 6, 25 Little 
is known about the relationship between CCR5 or its ligands and CRP 
during ESRD or dialysis. However, in one study, it has been observed that 
acute transcription of anti-inflammatory cytokines following HD was 
significantly lower in patients with high serum CRP levels.41 In contrast, 
transcription of pro-inflammatory cytokines (including IL-1β and TNF-α) was 
induced in equal concentrations, regardless of baseline CRP levels. IL-1β 
and TNF-α are known to induce expression of the CCR5 ligands CCL4 and 
CCL5 in renal disease.42, 43 Thus, the diminished up regulation of anti-
inflammatory cytokines, together with enhanced expression of cytokines that 
stimulate CCR5 mediated inflammation, could underlie the observed hsCRP-
dependent increased mortality in dialysis patients homozygous for a 
functional CCR5 gene in our study.  
A potential limitation of our study is that we were not able to study all 
included patients from the NECOSAD cohort, because data on hsCRP 
and/or CCR5 were not available in a subset of the patients. In this subset, 
mortality rate was slightly higher than in the patients available for analysis. In 
a single-cohort study, selection bias and population stratification cannot be 
excluded, despite the presence of Hardy-Weinberg equilibrium, and despite 
confirmation of results when only the Caucasian subjects were analysed. 
However, independent replication on a Swedish cohort, that was in Hardy 
Weinberg equilibrium as well, and in which data were available for all 
patients confirmed our results, hereby showing the robustness of our 
findings. As, moreover, the number of patients in the CCR532 groups was 
small, we did an analysis on the two cohorts combined, leading to the same 
results.  
A single value of hsCRP was used in our analysis. It is possible that the 
hsCRP level was elevated because of acute infectious reasons and not due 
to a persistent inflammatory state. To exclude patients with an acute 
infection the analyses were redone by excluding patients with a 
CRP>50mg/l. This resulted in comparable HRs for all-cause and 
cardiovascular mortality. For non-cardiovascular mortality the HRs were 
comparable with those found for cardiovascular mortality, thereby 
underlining the importance of the CCR5 genotype in chronic, inflammation 
driven mortality.  
We used the previously used hsCRP cut-off point of 10mg/l to divide patients 
in a group with or without a chronic inflammatory state. This cut-off point 
could potentially have influenced our results. However, analyzing the 
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interaction between CCR5 genotype and CRP level with the median hsCRP 
level as cut-off did not alter the results. Moreover, when analyzing hsCRP as 
a continuous variable, the hsCRP level seemed to influence mortality and 
cardiovascular mortality in the CCR5 ins/ins genotype group and not in the 
CCR532 genotype group. 
Adjustments in genetic association studies could potentially introduce 
interference in the causal pathway and thereby bias through 
overadjustment.44 For this reason, we reported unadjusted hazard ratios in 
the manuscript. However, as we studied CCR5 as effect modificator of the 
association between CRP levels and mortality, and CRP levels can be 
affected by confounding variables, like cardiovascular disease, diabetes and 
dialysis modality, we also reported adjusted hazard ratios in the manuscript.  
Finally, we only studied a single polymorphism. The observed effect does 
not necessarily causally implicate this particular polymorphism, but could be 
due to another variant in linkage disequilibrium with the studied deletion. 
This variant does not necessarily have to be located within the CCR5 gene, 
since patterns of linkage disequilibrium do not follow the patterns of genes in 
the genome. This is a point that deserves further investigation. However, our 
efforts as reported in the present study were not toward in-depth 
characterization of the gene locus, but rather to investigate whether the 
impact of the polymorphism, reported in the literature to be associated with 
mortality, was modified by inflammatory status.  
In conclusion, our results indicate that CCR5 genotype modifies the 
prognosis of mortality associated with inflammation in incident dialysis 
patients. Data from the literature suggest that this could be due to CCR5 
deficiency (implicated by one or two copies of a non-functional CCR5 gene). 
This could lead to attenuation of the adverse effects of a persistent 
inflammatory state that is involved in increased all-cause and cardiovascular 
mortality in dialysis patients. Recently CCR5 blockade has become feasible 
in humans.45 Our data suggest that is may be worthwhile to study whether 
pharmacological blockade of CCR5 could have therapeutic benefits in 
dialysis patients with persistent inflammation.  
 
Acknowledgements 
This work was supported by the applied GENomic stratEgies for Treatment 
and Prevention of Cardiovascular death in Uraemia and End stage REnal 
disease (GENECURE) project (www.genecure.eu), a Specific Targeted 
Research or Innovation Project, funded by the European Commission under 
the Sixth Framework Programme as FP6-037696. GENECURE is led by 
prof. dr. G.J. Navis, University Medical Center Groningen in Groningen, The 
Netherlands; its goal is to elucidate the genomic basis of cardiovascular 
55 
 
complications in renal disease. GENECURE is hosted by the Renal Genome 
Network (ReGeNet) project (www.regenet.eu), a pan European network of 
clinicians and scientists from academia and industry seeking to generate 
and facilitate genetic and genomic studies to the clinical benefit of the renal 
patient.  




 1.  Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular 
disease in chronic renal disease. J Am Soc Nephrol 1998; 9(12 
Suppl):S16-S23. 
 2.  Lacson E Jr, Levin NW. C-reactive protein and end-stage renal 
disease. Semin Dial 2004; 17(6):438-448. 
 3.  Pearson TA, Mensah GA, Alexander RW et al. Markers of 
inflammation and cardiovascular disease: application to clinical and 
public health practice: A statement for healthcare professionals from 
the Centers for Disease Control and Prevention and the American 
Heart Association. Circulation 2003; 107(3):499-511. 
 4.  Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Bjorkegren J. 
Human C-reactive protein slows atherosclerosis development in a 
mouse model with human-like hypercholesterolemia. Proc Natl Acad 
Sci U S A 2007; 104(34):13768-13773. 
 5.  den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker 
FW. The effect of single and repeatedly high concentrations of C-
reactive protein on cardiovascular and non-cardiovascular mortality in 
patients starting with dialysis. Nephrol Dial Transplant 2006; 
21(6):1588-1595. 
 6.  Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, 
Krediet RT, Dekker FW. Excellent agreement between C-reactive 
protein measurement methods in end-stage renal disease patients--no 
additional power for mortality prediction with high-sensitivity CRP. 
Nephrol Dial Transplant 2007. 
 7.  Racki S, Zaputovic L, Mavric Z, Vujicic B, Dvornik S. C-reactive protein 
is a strong predictor of mortality in hemodialysis patients. Ren Fail 
2006; 28(5):427-433. 
 8.  Stenvinkel P. Inflammation in end-stage renal disease: the hidden 
enemy. Nephrology (Carlton ) 2006; 11(1):36-41. 
 9.  Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. 
Inflammation enhances cardiovascular risk and mortality in 
hemodialysis patients. Kidney Int 1999; 55(2):648-658. 
57 
 
 10.  Bursill CA, Channon KM, Greaves DR. The role of chemokines in 
atherosclerosis: recent evidence from experimental models and 
population genetics. Curr Opin Lipidol 2004; 15(2):145-149. 
 11.  Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular 
disease. Circ Res 2004; 95(9):858-866. 
 12.  Mach F. The role of chemokines in atherosclerosis. Curr Atheroscler 
Rep 2001; 3(3):243-251. 
 13.  Reape TJ, Groot PH. Chemokines and atherosclerosis. 
Atherosclerosis 1999; 147(2):213-225. 
 14.  Braunersreuther V, Mach F, Steffens S. The specific role of 
chemokines in atherosclerosis. Thromb Haemost 2007; 97(5):714-721. 
 15.  Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular 
cloning and functional characterization of a novel human CC 
chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. 
J Biol Chem 1996; 271(29):17161-17166. 
 16.  Schecter AD, Calderon TM, Berman AB et al. Human vascular smooth 
muscle cells possess functional CCR5. J Biol Chem 2000; 
275(8):5466-5471. 
 17.  Weber C, Schober A, Zernecke A. Chemokines: key regulators of 
mononuclear cell recruitment in atherosclerotic vascular disease. 
Arterioscler Thromb Vasc Biol 2004; 24(11):1997-2008. 
 18.  Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local 
expression of inflammatory cytokines in human atherosclerotic 
plaques. J Atheroscler Thromb 1994; 1 Suppl 1:S10-S13. 
 19.  Gonzalez P, Alvarez R, Batalla A et al. Genetic variation at the 
chemokine receptors CCR5/CCR2 in myocardial infarction. Genes 
Immun 2001; 2(4):191-195. 
 20.  Pai JK, Kraft P, Cannuscio CC et al. Polymorphisms in the CC-
chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of 
coronary heart disease among US women. Atherosclerosis 2006; 
186(1):132-139. 
 21.  Szalai C, Duba J, Prohaszka Z et al. Involvement of polymorphisms in 
the chemokine system in the susceptibility for coronary artery disease 
58 
 
(CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype 
in CAD patients. Atherosclerosis 2001; 158(1):233-239. 
 22.  Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 
coreceptor accounts for resistance of some multiply-exposed 
individuals to HIV-1 infection. Cell 1996; 86(3):367-377. 
 23.  Venkatesan S, Petrovic A, van Ryk DI, Locati M, Weissman D, Murphy 
PM. Reduced cell surface expression of CCR5 in CCR5Delta 32 
heterozygotes is mediated by gene dosage, rather than by receptor 
sequestration. J Biol Chem 2002; 277(3):2287-2301. 
 24.  van Dijk PC, Jager KJ, de Charro F et al. Renal replacement therapy 
in Europe: the results of a collaborative effort by the ERA-EDTA 
registry and six national or regional registries. Nephrol Dial Transplant 
2001; 16(6):1120-1129. 
 25.  Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in 
end-stage renal failure: does female gender constitute a survival 
advantage? Kidney Int 2002; 62(5):1791-1798. 
 26.  Clark VJ, Metheny N, Dean M, Peterson RJ. Statistical estimation and 
pedigree analysis of CCR2-CCR5 haplotypes. Hum Genet 2001; 
108(6):484-493. 
 27.  Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of 
transdominant inhibition of CCR5-mediated HIV-1 infection by 
ccr5delta32. J Biol Chem 1997; 272(49):30603-30606. 
 28.  Stenvinkel P, Heimburger O, Paultre F et al. Strong association 
between malnutrition, inflammation, and atherosclerosis in chronic 
renal failure. Kidney Int 1999; 55(5):1899-1911. 
 29.  KJ Rothman. Measuring interactions. In: epidemiology, New York, 
Oxford University Press, Inc., 2002, pp 168-180 
 30.  Veillard NR, Kwak B, Pelli G et al. Antagonism of RANTES receptors 
reduces atherosclerotic plaque formation in mice. Circ Res 2004; 
94(2):253-261. 
 31.  Schober A, Manka D, von Hundelshausen P et al. Deposition of 
platelet RANTES triggering monocyte recruitment requires P-selectin 




 32.  van Wanrooij EJ, Happe H, Hauer AD et al. HIV entry inhibitor TAK-
779 attenuates atherogenesis in low-density lipoprotein receptor-
deficient mice. Arterioscler Thromb Vasc Biol 2005; 25(12):2642-2647. 
 33.  Simeoni E, Winkelmann BR, Hoffmann MM et al. Association of 
RANTES G-403A gene polymorphism with increased risk of coronary 
arteriosclerosis. Eur Heart J 2004; 25(16):1438-1446. 
 34.  Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 
infection and progression to AIDS by a deletion allele of the CKR5 
structural gene. Hemophilia Growth and Development Study, 
Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, 
San Francisco City Cohort, ALIVE Study. Science 1996; 
273(5283):1856-1862. 
 35.  Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is 
mediated by the chemokine receptor CC-CKR-5. Nature 1996; 
381(6584):667-673. 
 36.  Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in 
caucasian individuals bearing mutant alleles of the CCR-5 chemokine 
receptor gene. Nature 1996; 382(6593):722-725. 
 37.  Braunersreuther V, Zernecke A, Arnaud C et al. Ccr5 but not Ccr1 
deficiency reduces development of diet-induced atherosclerosis in 
mice. Arterioscler Thromb Vasc Biol 2007; 27(2):373-379. 
 38.  Potteaux S, Combadiere C, Esposito B et al. Role of bone marrow-
derived CC-chemokine receptor 5 in the development of 
atherosclerosis of low-density lipoprotein receptor knockout mice. 
Arterioscler Thromb Vasc Biol 2006; 26(8):1858-1863. 
 39.  Quinones MP, Martinez HG, Jimenez F et al. CC chemokine receptor 
5 influences late-stage atherosclerosis. Atherosclerosis 2007; 
195(1):e92-103. 
 40.  Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C. 
Deficiency in CCR5 but not CCR1 protects against neointima 
formation in atherosclerosis-prone mice: involvement of IL-10. Blood 
2006; 107(11):4240-4243. 
 41.  Friedrich B, Alexander D, Janessa A, Haring HU, Lang F, Risler T. 
Acute effects of hemodialysis on cytokine transcription profiles: 
60 
 
evidence for C-reactive protein-dependency of mediator induction. 
Kidney Int 2006; 70(12):2124-2130. 
 42.  Schwarz M, Radeke HH, Resch K, Uciechowski P. Lymphocyte-
derived cytokines induce sequential expression of monocyte- and T 
cell-specific chemokines in human mesangial cells. Kidney Int 1997; 
52(6):1521-1531. 
 43.  van Kooten C, van der Linde X, Woltman AM, van Es LA, Daha MR. 
Synergistic effect of interleukin-1 and CD40L on the activation of 
human renal tubular epithelial cells. Kidney Int 1999; 56(1):41-51. 
 44.  Jager KJ, Zoccali C, Macleod A, Dekker FW. Confounding: what it is 
and how to deal with it. Kidney Int 2008; 73(3):256-260. 
 45.  Fatkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term 
monotherapy with maraviroc, a new CCR5 antagonist, in patients 







TNF-α levels are not increased in inflamed patients carrying the 
CCR5 deletion 32 
 
Friso L.H. Muntinghe1, Juan Jesus Carrero2, 3, 4, Gerjan Navis1, Peter 
Stenvinkel2 
 
1: University Medical Center Groningen, Internal Medicine, Groningen, the 
Netherlands 
2: Karolinska Institutet, University Hospital at Huddinge, Renal Medicine, 
Stockholm, Sweden 
3: Centre for Molecular Medicine, Stockholm, Sweden  
4: Centre for Gender Medicine, Stockholm, Sweden 
 
 






Recently we reported on a genetically predisposed protection from C-
reactive protein (CRP) related mortality in dialysis patients carrying the 
functional CC-chemokine receptor 5 deletion 32 allele (CCR5∆32) mutation. 
Since CCR5∆32 is associated with a less pro-inflammatory immune 
response in mice, we hypothesized that the observed protection is (in part) 
due to a less pro-inflammatory cytokine profile. 
We conducted a cross-sectional observational study including 263 incident 
dialysis patients aged 18-70 yrs, without clinical signs of infection and/or 
acute vasculitis. TNF-α, IL-6, IL-10 and hsCRP levels were determined and 
studied in relation to the CCR5 genotype. 
We showed that in the presence of elevated hsCRP, IL-6 concentration was 
higher irrespective of the CCR5 genotype. However, in patients with the 
CCR5 deletion, TNF-α did not differ in the presence/absence of elevated 
hsCRP and was not correlated with hsCRP levels in carriers of the 
CCR5∆32 polymorphism. 
So, a possible underlying mechanism of the impact of CCR5∆32 genotype 
on inflammation driven mortality in dialysis patients could be a reduced Th1 




We recently reported on a genetically predisposed protection from C-
reactive protein (CRP) related (cardiovascular) mortality in dialysis patients 
carrying the functional CC-chemokine receptor 5 deletion 32 allele 
(CCR5∆32) mutation.1 The CC-chemokine receptor 5 (CCR5) is expressed 
on monocytes and T-lymphocytes, especially Th1 cells.2 A common genetic 
polymorphism consisting of a 32-basepair deletion in the open reading frame 
results in functional CCR5 deficiency by absence of CCR5 membrane 
expression. Heterozygous subjects express a lower amount of functional 
receptors compared to wild-type homozygotes.3 Consistent with our findings, 
the CCR5∆32 polymorphism has been associated with better 
(cardiovascular) outcome in different populations.4-7 Whereas Th1 
responses, as well as the cytokines TNF-α and INF-γ are pro-inflammatory, 
as opposed to Th2 responses and IL-10.8, 9 IL-6 exhibits both pro- and anti-
inflammatory effects.10 Of the vast family of cytokines, TNF-α, IL-6 and IL-10 
seem to play a major role in the development of Th1/Th2 imbalance, leading 
to increased (cardiovascular) complications and worse outcome in end stage 
renal disease (ESRD) patients.11 In mice it has been shown that CCR5 
deficiency is associated with reduced Th1 type responses, less TNF-α and 
INF-γ production and increased secretion of the anti-inflammatory cytokine 
IL-10.12-15  
In this analysis, we hypothesize that the previous observed protection from 
CRP related (cardiovascular) mortality in CCR5∆32 polymorphism carriers is 
(in part) due to a less pro-inflammatory immune response in the carriers of 
the deletion. We tested this in a cohort of incident dialysis patients in whom 
levels of CRP, TNF-α, IL-6 and IL-10 were assessed and related to their 
CCR5∆32 genotype. 
 
Patients and Methods 
Study population 
This analysis is framed within a prospective follow-up study in well-
characterized chronic kidney disease (CKD) stage 5 patients sampled close 
to the start of renal replacement therapy from Karolinska University Hospital 
at Huddinge, Sweden, including patients of 18-70 years of age, without 
clinical signs of infection and/or acute vasculitis at time of admission. A 
detailed description was published previously.16 This cohort was used as 
independent replication in our previous study about the modification of 
CCR5∆32 on the association of CRP levels with mortality in ESRD patients. 
Diabetes and clinical history of cardiovascular disease (CVD) was recorded. 
Patients were divided in four groups according to their CCR5 genotype and 
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presence or absence of systemic inflammation defined by a high-sensitivity 
CRP (hsCRP) level >10 mg/l.1  
Laboratory analyses 
hsCRP, cholesterol, S-albumin and hemoglobin were analyzed using routine 
methods at the Karolinska University Hospital. Serum concentrations of 
TNF-α, IL-6 and IL-10 were quantified on the Immulite automatic analyzer 
(Diagnostic Products Corporation, Los Angeles, California, USA). Genotype 
analyses were performed by PCR amplification followed by size separation 
of the resulting fragments on a 3% agarose gel and visualization by ethidium 
bromide staining. The resulting fragments were 241 and 209 bp for the 
insertion and the deletion allele, respectively.  
Statistical analyses 
Hardy-Weinberg equilibrium was calculated using the gene-counting 
method. Differences between groups were tested with the chi-square test for 
dichotomous and categorical variables and one-way ANOVA for continuous 
variables. Spearman rank was used to test correlation. All statistical 
analyses were performed with SPSS statistical software (version 16.0; 
SPSS, Chicago, IL). 
 
Results  
Of 302 incident dialysis patients genotyped for CCR5, hsCRP level TNF-α, 
IL-6 and IL-10 levels were available in 263. No major differences were 
observed between the 263 included patients and those 39 with missing 
cytokine values. The CCR532 genotype was distributed as follows: ins/ins 
218 (82.9%), ins/32 41 (15.6%) and 32 /32 4 (1.5%) and did not deviate 
significantly (p=0.21) from Hardy-Weinberg equilibrium. Baseline 
characteristics of CCR532 carriers and non-carriers are given in the Table 
1. There were no differences in baseline characteristics between the two 
groups.  
No significant differences in TNF-α, IL-6 and IL-10 levels were observed 
between the genotype groups. However, when evaluating these cytokines 
stratified by the CCR5 genotype and hsCRP level, significant differences 
were observed for TNF-α and IL-6 but not for IL-10 levels (Table 2). In the 
presence of elevated hsCRP, IL-6 concentration was higher irrespective of 
the CCR5 genotype (p<0.01). However, in patients with the CCR5 deletion, 
TNF-α did not differ in the presence/absence of elevated hsCRP (p=0.81). 
To further investigate this finding univariate correlations between TNF-α, IL-6 
and hsCRP levels were studied (Table 3). As expected, whereas IL-6 was 
strongly associated with hsCRP (Rho=0.62) the correlation between hsCRP 
and TNF-α was modest (Rho=0.26). When patients were stratified by the 
CCR5 genotype, no association between hsCRP and TNF-α was observed 
among patients carrying the CCR532 polymorphism indicating that TNF-α 
levels are not elevated in patients carrying the deletion despite a higher state 
of inflammation.  
 
Table 1: Baseline characteristics according to CCR5 genotype. Data are presented 
as number (percentage), median (25, 75 percentile), mean (SD). GFR: glomerular 
filtration rate. No significant differences were observed between the groups. 
 
 




Gender: male 129 (59.2) 32 (71.1) 
Age (year)  55 (44-63) 54 (46-65) 
GFR (ml/min) 6.5 (2.2) 6.6 (2.8) 
Cardiovascular disease 
(%) 
72 (33.0) 12 (26.7) 
Diabetes mellitus (%) 69 (31.7) 12 (26.7) 
Cholesterol (mmol/l) 5.3 (1.5) 5.3 (1.3) 
Hemoglobin (g/l) 104 (14) 105 (16) 
Albumin (g/l)  32.9 (6.1) 33.6 (6.3) 
hsCRP (mg/l)   4.6 (2.1-14.0) 6.7 (2.2-18.0) 
TNF-α (pg/ml) 10.3 (8.0-13.5)  9.2 (7.8-11.4) 
IL-6 (pg/ml) 6.4 (3.5-10.9) 6.5 (3.7-9.1) 















Table 2: Levels (median, 25 and 75 percentile) of TNF-α, IL-6 and IL-10 according to 




 CCR5 ins/ins & 
hsCRP<10 mg/L 
n=147 
CCR5 del/ & 
hsCRP<10 mg/L 
n=26 
CCR5 ins/ins & 
hsCRP>10 mg/L 
n=71 





9.6 (7.5-12.6) 8.7 (7.5-11.9) 12.2 (9.1-15.2)* 10.4 (7.9-11.4) 
IL-6 
(pg/ml) 
4.6 (2.9-7.3) 3.8 (2.9-5.1) 11.1 (7.1-16.3)* 9.1 (8.1-15.6)* 
IL-10 
(pg/ml) 







This prospective study in incident dialysis patients suggest that our previous 
finding of an associating between mortality and elevated serum hsCRP 
concentrations is modulated by the CCR5∆32 polymorphism could be 
mediated via less TNF-α elevation in inflamed patients carrying the 
CCR5∆32 polymorphism. Whereas IL-6 was elevated in inflamed patients 
irrespective of their genotype IL-10 levels did not differ between the groups.   
TNF-α is the classical pro-inflammatory cytokine with a pivotal role in the 
regulation of other inflammatory mediators. Elevated serum levels of TNF-α 
are associated with increased mortality and atherosclerosis in dialysis 
patients.11, 17-19 The current observation that the association between an 
inflammatory trigger, as indicated by elevated hsCRP, and elevation of TNF-
α is modulated by CCR5∆32 is in accordance with animal reports where 
CCR5 deficiency was associated with reduced Th1 type responses, less 
TNF-α and INF-γ production; opposite to the animal data in this study IL-10 
levels were not increased in human carriers of the CCR5∆32 genotype.12-15 
Acknowledged limitations in this study are the relatively small sample size 
and the existence of some data exclusions due to missing cytokine 
measurements. Besides this only patients from the validation cohort are 
incorporated in this study due to absence of cytokine levels in the other 
cohort used in our previous study.1 
In conclusion, our results suggest that one underlying mechanism of the 
impact of CCR5∆32 genotype on inflammation driven mortality in ESRD 
patients might be a reduced Th1 immune response trough less TNF-α 
production. This hypothesis needs to be tested in larger patient groups. 
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In patients with end stage renal disease (ESRD) we observed protection 
from inflammation-associated mortality in CCR5∆32 carriers, leading to 
CCR5 deficiency, suggesting impact of CCR5∆32 on inflammatory 
processes. Animal studies have shown that CCR5 deficiency is associated 
with a more pronounced Th2 type immune response, suggesting that in 
human CCR5∆32 carriers the immune response may be more Th2 type 
directed. So, in the present study we determined the Th1-Th2 type directed 
immune response in ESRD patients carrying and not carrying the CCR5∆32 
genetic variant after stimulation.  
Methodology/Principal Findings 
We tested this hypothesis by determining the levels of IFN-γ and IL-4 and 
the distribution of Th1, Th2 and Th17 directed circulating CD4+ and CD8+ T 
cells and regulatory T cells (Tregs) after stimulation in ESRD patients with 
(n=10) and without (n=9) the CCR5∆32 genotype. The extracellular levels of 
IFN-γ and IL-4 did not differ between CCR5∆32 carriers and non carriers. 
However, based on their intracellular cytokine profile the percentages IL-4 
secreting CD4+ and CD8+ T cells carrying the CCR5∆32 genotype were 
significantly increased (p=0.02, respectively p=0.02) compared to non 
carriers, indicating a more Th2 type directed response. Based on their 
intracellular cytokine profile the percentages IFN-γ and IL-17 secreting T 
cells did not differ between carriers and non-carriers nor did the percentage 
Tregs, indicating that the Th1, Th17 and T regulatory response was not 
affected by the CCR5∆32 genotype.  
Conclusions/Significance 
This first, functional human study shows a more pronounced Th2 type 
immune response in CCR5Δ32 carriers compared to non carriers. These 
differences may be involved in the previously observed protection from 




Genetic variability in the chemokine cascades could potentially influence 
disease outcomes by modifying inflammatory processes. CC-chemokine 
receptor 5 (CCR5) is one of the chemokine receptors. It is expressed on T 
cells and monocytes and it is important for recruitment.1,2 Several 
polymorphisms have been described for CCR5. The CCR5∆32 genetic 
variant is located on the chromosome 3p21 and consists of a 32-basepair 
deletion in the open reading frame. It effectively results in functional CCR5 
deficiency by absence of CCR5 membrane expression.3 We observed 
protection from inflammation-associated mortality in carriers of the deletion 
32 allele in end stage renal disease (ESRD), suggesting impact of CCR5∆32 
on the inflammatory process of atherosclerosis.4 Also in other human 
populations, characterized by high cardiovascular risk, the presence of the 
CCR5∆32 genotype has been associated with better outcome.5-8  
In chronic inflammatory processes like atherosclerosis T cells play an 
important role. Both CD4+ T cells and to a lesser extent CD8+ T cells are 
present in atherosclerotic lesions.9-12 CD4+ T helper cells can differentiate 
into three effector lineages based on their cytokine expression: IFN-/TNF- 
producers (Th1), IL-4 producers (Th2) and IL-17 producers (Th17).12,13 In 
addition, a small fraction of CD4+ T cells can develop into cells with a 
regulatory function (Tregs) that are defined by their co-expression of high 
levels of surface CD25 and intracellular transcription factor forkhead box P3 
(FoxP3). These Tregs have the remarkable ability to suppress 
the proliferation and effector function of other T cells.9,12 As with CD4+ T 
cells, CD8+ T cells can differentiate to T cytotoxic (Tc)1 or Tc2 cell subsets, 
secreting predominantly Th1 or Th2 cytokines respectively.13  
Atherosclerotic inflammation is regarded as a (partly) Th1 driven condition.12 
The CCR5 receptor is highly expressed T-lymphocytes, on both CD4+ T and 
CD8+ T cells.2,11 In atherosclerotic mice CCR5 deficiency is associated with 
a more pronounced Th2 type immune response and less TNF-α and IFN-γ 
production hereby counteracting the Th1 directed Th1/Th2 disequilibrium of 
atherosclerotic inflammation.14-17 
These data fuel the hypothesis that the immune response in carriers of the 
CCR5∆32 genotype is more Th2 type directed. Such differences in response 
might play a role in the protection against inflammation-associated mortality 
in ESRD in carriers of the CCR5∆32 genotype. To test this hypothesis we 
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studied the cell mediated immune responses in peripheral mononuclear cells 
(PBMCs) in ESRD patients. We first determined the extracellular levels of 
IFN-γ and IL-4 after stimulation of PBMCs, and second the distribution of 
Th1, Th2 and Th17 directed circulating CD4+ and CD8+ T cells, based on 
their intracellular cytokine profile after stimulation, and the percentage of 




The objective of the present study was to determine possible differences in 
cell mediated immune response between ESRD carriers and non carriers of 
the CCR5∆32 genotype. To test this hypothesis we first determined the IFN-
γ and IL-4 levels after stimulation of peripheral mononuclear cells (PBMCs) 
and secondly the distribution of Type-1, Type-2 and Type-17 directed 
circulating CD4+ and CD8+ T cells, based on their intracellular cytokine 
profile, as well as the frequency of FoxP3+ regulatory T cells. 
Participants 
Biosamples and data from twenty patients with ESRD were included in this 
study. These patients were part of an ESRD cohort from a single kidney 
transplant centre in the Netherlands (University Medical Center Groningen), 
in whom data and biosamples were collected prior to kidney transplantation. 
As part of a larger genotyping project, all patients were genotyped as 
described below. For the current project we randomly selected five homo- 
and five heterozygous carriers from the cohort. Ten wild type patients were 
matched with carriers according to time of inclusion, hereby creating similar 
preservation conditions. 
Genotyping 
The genotypes were determined with a PCR-based allelic discrimination 
assay using primers (Life Technologies) and allele-specific probes (PE 
Biosystems) as described previously.18 Patients were grouped by CCR5 
genotype, namely those homozygous for the major allele (non-carriers) and 
those with 1 or 2 deletion alleles (carriers). Patients with one or two deletion 
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alleles were grouped together, as it has been demonstrated that presence of 
one deletion allele is sufficient to compromise CCR5 function.3  
Sample preparation and thawing 
Heparinized venous blood was obtained from ESRD-patients who gave their 
informed consent. PBMCs were separated by conventional Ficoll gradient 
and frozen in 10% DMSO in FCS and stored in liquid nitrogen. PBMCs were 
thawed and washed twice with RPMI 1640 media (Cambrex Bio Science, 
Verviers, Belgium), supplemented with 10% heat inactivated fetal calf serum 
and 50 μg/mL gentamycin (Gibco, Scotland, UK). 
Determination of extracellular cytokine by ELISA 
Thawed PBMCs were cultured in a 5mL polypropylene tubes (BD 
Biosciences) at 2,5 x106 cells/mL per tube, and stimulated with 40 nM 
phorbol myristate acetate (PMA; Sigma-Aldrich, Steinheim, Germany) and 2 
nM calcium ionophore (Sigma-Aldrich). Culture supernatants were collected 
over a period of 24 hours to determine the extracellular levels of IFN-, and 
IL-4 cytokines. 
Cytokine levels of IFN- and IL-4 were measured by commercial sandwich 
enzyme linked immunoassay (ELISA) kits (Pelikine Compact, Sanquin, 
Amsterdam, The Netherlands), according to the instructions of the 
manufacturer. 
Determination of intracellular cytokine by flow cytometry 
The following conjugated antibodies were used in flow cytometry: 
allophycocyanin (APC)–Cy7–conjugated anti-CD69, peridin-chlorophyll 
protein (PerCP)–conjugated anti-CD8, phycoerythrin (PE)– Cy7–conjugated 
anti–IL-4, and Alexa Fluor 700–conjugated anti-IFN-γ (all from Becton & 
Dickinson, Amsterdam, The Netherlands). Alexa Fluor 488–conjugated anti–
IL-17, Alexa Fluor 647-conjugated anti-TNF-, and eFluor605™–conjugated 
anti-CD3 were obtained from eBioscience (San Diego, CA). To determine 
the frequency of T cell subsets by measuring intracellular cytokine 
production, cells were stimulated for 4 hours with 40 nM PMA and 2 nM 
calcium ionophore. Brefeldin A (10μg/mL) was added to inhibit cytokine 
release. After stimulation, cells were washed in wash buffer (phosphate 
buffered saline, 5% fetal bovine serum, 0.1% sodium azide; Merck, 
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Darmstadt, Germany) and stained with eFluor 605-conjugated anti-CD3, 
PerCP–conjugated anti-CD8 and APC-Cy7–conjugated anti-CD69 for 15 
minutes at room temperature. Cells were fixed with 100 μl Reagent A 
(Caltag, An Der Grab, Austria) for 15 minutes. After washing, the pellet was 
resuspended in 100 μl permeabilization Reagent B (Caltag) and labeled with 
PE-Cy7–conjugated anti–IL-4, Alexa Fluor 700–conjugated anti-IFN-γ, Alexa 
Fluor 647-conjugated anti-TNF-, Alexa Fluor 488–conjugated anti–IL-17, 
and APC-Cy7–conjugated anti-CD69 for 30 minutes in the dark. After 
staining, the cells were washed and immediately analyzed on a FACS-LSRII 
flow cytometer (Becton Dickinson). Seven-color flow cytometric acquisition 
was performed using FACSDiva software (Becton Dickinson). For all flow 
cytometry analyses, data were collected for 2 x 105 cells and plotted using 
the Win-List software package (Verity Software House, Topsham, ME). 
Because stimulation reduces surface expression of CD4 on T cells, CD4 T 
cells were identified indirectly by gating on CD3+ and CD8− lymphocytes, 
whereas CD8+ T cells were identified by directly gating on CD3+ and CD8+ 
lymphocytes. Subsets of activated CD4+ and CD8+ T cells in response to 
mitogenic stimulation were evaluated by double expression of activation 
marker CD69 and intracellular cytokine production of IFN- (for type-1) or IL-
17 (for type-17) or IL-4 (for type-2). The unstimulated samples were used as 
a guide for setting the linear gates to delineate positive and negative 
populations. 
Determination of regulatory T cell frequencies 
PBMCs were washed with cold PBS (pH 7.2) and incubated with appropriate 
concentrations of PerCP-conjugated anti-CD4, FITC-conjugated anti-CD3 
and PE-conjugated anti-CD25 (all purchased from BD) for 30 min at 4 °C in 
the dark. Cells were then washed with cold PBS, followed by fixation and 
permeabilization in Fix/Perm buffer (FoxP3 staining kit, eBioscience, 
Uithoorn, The Netherlands) for 45 min at 4 °C. Subsequently, cells were 
washed with cold permeabilization buffer (FoxP3 staining kit, eBioscience, 
Uithoorn, The Netherlands). To block nonspecific binding, normal rat serum 
was added for 10 min, followed by the addition of APC-conjugated rat anti-
human FoxP3 (eBioscience, Uithoorn, The Netherlands). After incubation for 
30 min at 4 °C, the cell suspension was washed twice with cold 
permeabilization buffer, and immediately analyzed on FACS-Calibur (BD). 
Data were collected for 2 x 105 cells and plotted using the Win-List software 
package (Verity Software House, Topsham, ME). Positively and negatively 
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stained populations were calculated by quadrant dot-plot analysis, 
determined by the isotype matched control antibodies of irrelevant specificity 
(obtained from BD and eBioscience). 
Ethics 
All patients gave written informed consent and the local medical ethics 
committee from the University Medical Center Groningen (METc UMC 
Groningen), the Netherlands, gave their approval. 
Statistical methods 
Patients were grouped by CCR5 genotype, namely those homozygous for 
the major allele (non-carriers) and those with 1 or 2 deletion alleles 
(carriers). The latter were grouped together, as it has been demonstrated 
that presence of one deletion allele is sufficient to compromise CCR5 
function.3 Data are presented as the median. The nonparametric Mann-
Whitney U test was used to compare data from patients with and without the 
CCR5∆32 genotype. Differences were considered statistically significant at 
2-sided p values less than 0.05. 
 
Table 1: Baseline characteristics 
 
 CCR5 wild type 
(n= 9) 
CCR5 deletion 32 
(n=10) 
Gender; male 4 (44.4) 7 (70.0) 
Age (year) 51 (14) 51 (13) 
Primary kidney disease 
Renal vascular disease and hypertension 
Diabetes mellitus 


















Dialysis duration (days) 1570 (880) 1005 (734) 
Hemodialysis 5 (55.6) 4 (44.4) 
Body Mass Index 26 (4.94) 25 (3.21) 
Systolic bloodpressure (mmHg) 147 (19) 138 (10) 
Diastolic bloodpressure (mmHg) 86 (8) 86 (9) 
 




From the 20 patients who were included in this study 1 stimulation test failed 
due to the fact that the T cells could not be stimulated. Further statistical 
analyses were performed on the remaining 19 patients. Baseline 
characteristics are shown in Table 1. There were no statistically significant 
differences in baseline characteristics between the 2 genotype groups. 
Extracellular cytokines of type-1 and type-2 T cells 
To assess the functional capacity of the responding PBMCs the total amount 
of IFN- and IL-4 after stimulation was determined. As shown in Figure 1, the 
levels of extracellular IFN- and IL-4 were not statistically significant different 
between carriers and non carriers of the CCR5∆32 genotype. 
 
 
Figure 1: IFN-γ and IL-4 ELISA per 2,5 x 106 PBMCs in carriers and non carriers of 
the CCR5∆32 genotype. Levels of IFN-γ and IL-4 after stimulation from carriers 
(n=10) and non carriers (n=9) are shown. Horizontal lines represent the medians. 
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Intracellular cytokines of type-1, type-2, and type-17 T cells 
To elucidate the functional phenotype of the CD4+ and CD8+ T cells 
responding to stimulation, activated T cells were gated and evaluated for 
expression of the activation marker CD69 versus intracellular expression of 
the cytokines IFN-γ, IL-17 and IL-4. The results are shown in Figure 2 and 3. 
The percentages IL-4 secreting CD4+ and CD8+ T cells from patients with 
the CCR5∆32 genotype was significantly (p= 0.02, respectively p= 0.02) 
increased compared to patients not carrying the CCR5∆32 genotype, 
indicating a more Th2 type directed response. The percentages IFN-γ 
secreting CD4+ and CD8+ T cells did not significantly differ between carriers 
and non carriers of CCR5∆32, meaning the Th1 and Th17 response did not 
differ between these 2 groups. Comparing the CCR5∆32 homozygous and 
heterozygous CD4+ and CD8+ T cells showed no significant differences. 
 
 
Figure 2: Flow cytometric characterization of CD4 and CD8 T cell subsets from 
CCR5 wild type (left panel) and CCR5 deletion 32 (right panel). PBMCs were 
stimulated in vitro with PMA and Ca-ionophore for 4 hours in the presence of BFA. 
The CD4 and CD8 T cell subsets were then assessed for the expression of activation 
marker CD69 versus intracellular cytokine (IFN-γ, IL-17, and IL-4). The percentage in 
the upper right corner of each plot represents the net percentage of positive cells. 
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 Figure 3: Percentages of IL-4, IL-17 and IFN-γ secreting CD4 and CD8+ T cells in 
carriers and non carriers of the CCR5∆32 polymorphism. In the left panel the 
frequencies of IL-4, IL-17 and IFN-γ secreting cells among CD69+, CD4+ T cells from 
non carriers (n=9) and carriers (n=10) of the CCR5∆32 genotype are shown. In the 
right panel the frequencies of IL-4, IL-17 and IFN-γ secreting cells among CD69+, 
CD8+ T cells from non carriers (n=9) and carriers (n=10) of the CCR5∆32 
polymorphism are shown. Horizontal lines represent the median percentage. 
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Frequencies of regulatory T cells 
To address the question whether differences in Tregs frequencies influence 
the distribution of T cell subsets between CCR5Δ32 carriers and non 
carriers, FoxP3+CD25HighCD4+ T cells were analyzed in both groups. No 
significant differences were found between the 2 genotype groups (Figure 
4). It seems, therefore, that Tregs are not responsible for the differences in 






Figure 4: Percentages of Tregs (FoxP3+CD25High CD4+ T cells) in carriers and non 







In the present study we demonstrate a skewing of circulating CD4+ and 
CD8+ T cells towards the Th2 phenotype based on their intracellular 
cytokine profile after stimulation in ESRD patients carrying the CCR5∆32 
genotype. These data are in line with animal data showing that genetic 
deficiency of CCR5 results in a shift in immune response towards a Th2 type 
response, and support the assumption that genetic differences in immune 
response are involved in the protection against inflammation-associated 
mortality in ESRD patients reported previously.4  
In ESRD patients cardiovascular disease is a main cause of premature 
deaths.19 Chronic inflammation is a major contributing factor.20,21 The 
inflammatory nature of the process of atherosclerosis is nowadays well 
recognized.22 In this process T cells play an important role.9-12 Th1 cells, 
which produce IFN-γ as the principal cytokine, are thought to be pro-
inflammatory and pro-atherogenic and are the most prevalent subtype in 
atherosclerotic lesions; Th2 cells, with IL-4 as the major cytokine, have the 
ability to inhibit Th1 differentiation and could therefore be anti-atherogenic. 
The role of Th17 cells, producing IL-17, in atherosclerosis is not yet clear.23 
So, until now atherosclerotic inflammation is regarded as a Th1 directed 
Th1/Th2 disequilibrium.12 
To our knowledge, this is the first functional study investigating the Th1/Th2 
directed immune response in relation to the CCR5∆32 genetic variant in 
human. Animal studies consistently show a more pronounced Th2 immune 
response during genetic deficiency of CCR5 or pharmacological CCR5 
blockade in atherosclerotic and other inflammatory conditions. In diet 
induced atherosclerotic inflammation in mice, genetic deletion of CCR5 was 
associated with a more stable plaque phenotype and reduced Th1 type 
immune response of stimulated splenocytes and an increased Th2 type 
response in splenocytes and lymph node cells.14 After wire injury in mice 
with CCR5 deficiency a more atheroprotective immune response was seen, 
i.e. low IFN-γ and elevated IL-10 in CD4+ splenocytes compaired to CCR5 
wild type mice.15 Also in genetically CCR5 deficient mice with diet induced 
atherosclerosis, reduced lesion size, increased IL-10 and decreased TNF-α 
production by CD4+ and CD8+ T cells,16 and reduced macrophage 
accumulation in plaques and lowered circulating IL-6 levels was seen.17 In 
CCR5 deficient mice a more CD4+ Th2 cell activation pattern was seen in 
colitis in contrast to CCR5 wild type mice.24 Interestingly, in CCR5 
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genetically deficient mice who received a renal allograft less Th1 associated 
markers and increased Th2 associated markers were found during chronic 
intragraft immune response.25 In an islet transplantation model it was shown 
that in genetically CCR5 deficient mice not only in the intragraft immune 
response but also in the periphery a Th2 shift occurred.26 In mice with diet-
induced atherosclerosis treatment with a RANTES chemokine antagonist, 
hereby blocking CCR5, reduced atherosclerotic plaque formation, 
associated with reduced proliferation and secretion of Th1 cytokines IFN-γ 
and TNF-α, without difference in Th2 cytokine profile.27 In rats 
pharmacological CCR5 blockade in stimulated endothelial cells inhibited 
selective transmigration of CD4+ Th1 cells.28  
Our results extend these animal data on functional differences in immune 
response for the first time to a human setting and support our previous 
human cross-sectional association study, showing absence of association 
between serum CRP and TNF-α levels in ESRD patients carrying the 
CCR5∆32 genotype, in contrast to patients without this genetic variant, 
supporting a reduced Th1 immune response in CCR5∆32.29 It should be 
emphasized that ELISA and flowcytometry methods give different types of 
results and that measuring the intracellular cytokine production by FACS is 
more accurate than ELISA. The measured cytokines by ELISA can be 
released from several cells, whereas FACS-method identifies the 
intracellular cytokines produced on a single-cell level. In addition, difference 
in T cell numbers between the study samples may influence the results 
obtained from ELISA but not from FACS method hereby probably explaining 
why we did not find a difference in extracellular cytokine levels between 
CCR5∆32 carriers and non carriers. Since Tregs are responsible for 
regulation and suppression of T cell responses,9,12 one may argue that 
differences in Tregs could underlie the increase in IL-4 expression in 
CCR5∆32 carriers. However, no significant differences were observed in the 
percentages of Tregs between CCR5∆32 carriers and non carriers. Thus, 
the increased Type 2 response in CCR5∆32 carriers cannot be related to 
different frequencies of Tregs.  
Together, these findings provide an explanation for the previously observed 
protection from inflammation-related mortality in ESRD in CCR5∆32 carriers, 
as they support a less pro-inflammatory, pro-atherogenic immune response 
in carriers of the deletion.4 Our results could also provide a mechanism 
underlying the protection against atherosclerosis by pharmacological 
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blockade of the CCR5 pathway in animal studies.30-32 Of note, CCR5 
blockade has become feasible in humans, and is currently used for 
treatment of HIV-infection.33 It has been proposed that CCR5 blockade may 
be a strategy for protection against inflammation driven cardiovascular 
disease in ESRD and/or transplantation.34,35 Our current results contribute to 
understanding of mechanisms that could be affected by CCR5 blocking 
agents in ESRD.  
Limitations 
Acknowledged limitation in this study is the relatively small sample size. 
Besides this one blood sample failed to be stimulated. However, as 
mentioned above, the results are in accordance with animal data and extend 
the findings of a correlation study in ESRD patients, supporting the 
robustness of our findings. Another limitation is that we studied ESRD 
patients only. ESRD as such affects T-cell properties.36 Whereas the effects 
of CCR5 deficiency appear to be remarkably consistent across different 
species and inflammatory conditions, nevertheless generalization of our 
results to other populations would require a separate study.  
In conclusion, we present the first human data on a difference in Th1/Th2 
balance dependent on the CCR5∆32 genotype in ESRD patients. Stimulated 
CD4+ and CD8+ T cells of patients with one or two CCR5∆32 alleles show 
an increased Th2 type phenotype base on their intracellular cytokine profile. 
Differences in immune response may be involved in the impact of CCR5∆32 
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Randomized clinical trials are expensive and time-consuming. Therefore, 
strategies are needed to prioritize tracks for drug development. Genetic 
association studies may provide such a strategy by considering the 
differences between genotypes as a proxy for a natural, lifelong, randomized 
at conception, clinical trial. Previously an association with better survival was 
found in dialysis patients with systemic inflammation carrying a deletion 
variant of the CC-chemokine receptor 5 (CCR5∆32). We hypothesized that 
in an analogous manner, pharmacological CCR5 blockade could protect 
against inflammation driven mortality and estimated if such a treatment 
would be cost-effective. 
A genetic screen-and-treat strategy was modelled using a decision-analytic 
Markov model, in which patients were screened for the CCR5∆32 
polymorphism and those with the wild type and systemic inflammation were 
treated with pharmacological CCR5 blockers. Kidney transplantation and 
mortality rates were calculated using patient level data. Extensive sensitivity 
analyses were performed. 
The cost-effectiveness of the genetic screen-and-treat strategy was €18,557 
per life-year gained and €21,896 per QALY gained. Concordance between 
the genetic association and pharmacological effectiveness was a main driver 
of cost-effectiveness. Sensitivity analyses showed that even a modest 
effectiveness of pharmacological CCR5 blockade would result in a treatment 
strategy that is good value for money. 
Pharmacological blockade of the CCR5 receptor in inflamed dialysis patients 
can be incorporated in a potentially cost-effective screen-and-treat program. 
These findings provide formal rationale for clinical studies. This study 
illustrates the potential of genetic association studies for drug development, 






Pharmacological interventions that are of benefit in non-dialysis populations 
have thus far been disappointing in dialysis patients, underscoring the need 
for novel intervention strategies, specifically targeted at the dialysis 
population.1, 2 However, development of novel pharmacological approaches 
followed by randomized clinical trials is expensive and time consuming, 
providing an immense obstacle to the development and introduction of 
innovative approaches in patient care. Research and development costs for 
a single approved cardiovascular drugs can reach hundreds of millions of 
dollars, with most costs accrued in phase II and III trials.3 Therefore, 
alternative strategies are urgently needed to facilitate the multi-faceted 
process from drug development to introduction in clinical practice. 
Observational studies using genetic variants might provide such a strategy.4 
Given the random assignment of alleles in gamete formation, genetic 
variants can be considered to mimic the randomization process of 
randomized clinical trials. Data obtained through genetic association studies 
could therefore be considered a type of natural, lifelong, clinical trial, with 
genetically different groups being randomized at conception, hereby limiting 
confounding. This approach is known as Mendelian randomization.5, 6  
One of the main driving forces in the accelerated atherosclerosis in end 
stage renal disease (ESRD) patients is chronic inflammation.7 This 
population might therefore benefit from alternative therapies directed against 
the chronic inflammatory response. In this inflammatory process chemokines 
and chemokine receptors play an important role.8-10 One of the chemokine 
receptors involved is the CC-chemokine 5 receptor (CCR5). Animal data 
show that pharmacologic intervention in the CCR5 chemokine pathway 
reduces atherosclerosis.11-13 The relevance of these findings for humans is 
supported by genetic association studies on the CCR5 deletion 32 
(CCR5∆32) polymorphism, leading to functional CCR5 deficiency.14 These 
studies show that CCR5∆32 is associated with better outcome in different 
populations.15-18 Previously, we found that CCR5∆32 was associated with 
protection against mortality in Dutch cohort of dialysis patients characterized 
by inflammation and replicated these findings a in Swedish cohort.19 Taken 
together, these data suggest that intervention targeting inflammation, in 
particular targeting the CCR5, may have the potential to improve prognosis 
in ESRD.20  
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Interestingly, pharmacological blockade of CCR5 is feasible in human as it is 
applied in clinical practice for treatment of HIV infection, which increases the 
feasibility of development of CCR5 blockade as a treatment strategy for 
protection against inflammation-driven atherosclerosis in ESRD.21  
In line with the above, genetic association data on long term outcome in 
patients with versus without CCR5∆32 can be considered as a virtual long 
term randomized intervention study on pharmacological blockade of the 
CCR5 receptor providing a fast and cheap simulation set-up for a real-life 
clinical trial. Systematic reviews have shown that pharmacogenetic screen-
and-treat programs show great potential for developing cost-effective 
treatment modalities.22, 23 In the current analysis, we use these concepts to 
estimate the potential cost-effectiveness of CCR5Δ32 screening and 
pharmacological CCR5 blockade in dialysis patients, from the perspective of 




For the present study we used data from our previously published study on 
the effect of the CCR5∆32 polymorphism on inflammation associated 
mortality in dialysis patients. This study was part of the NEtherlands 
COoperative Study on the Adequacy of Dialysis (NECOSAD), a multicenter 
prospective follow-up study comprising incident (new and consecutive) 
ESRD patients from 38 Dutch dialysis centers included between July 1998 
and December 2001. Detailed descriptions of the study design and results 
have been published previously.19  
Eligibility criteria for inclusion in the NECOSAD cohort were 18 years or 
older and no previous renal replacement therapy. All patients gave informed 
consent and all local medical ethics committees gave their approval. 
Patients were evaluated at 3 and 6 months after start of dialysis and every 6 
months thereafter until death or date of censoring. Censoring involved 
transfer to a non-participating dialysis center, withdrawal from the study or 
end of the follow-up period in June 2007. Patients receiving a kidney 
transplant were not censored; data on their survival were obtained from the 
Dutch renal registry (RENINE). 
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Data collection and clinical definitions 
High sensitivity CRP (hsCRP) was measured by means of particle-enhanced 
immunonephelometry using a standard CardioPhase hsCRP for BNII (Dade 
Behring Holding GmbH, Liederbach, Germany; detection limit 0.1 mg/l, 
precision 0.1 mg/l).24 Systemic inflammation was defined as hsCRP 
concentrations above 10 mg/l. This cut-off point has been used in ESRD 
patients and has been validated with regard to the prediction of survival of 
ESRD patients.25 Also it was demonstrated that a single measurement of 
elevated CRP levels was associated with a similar predictive power on 
mortality as repeated CRP measurements.26   
CCR5 genotypes were determined with a PCR-based allelic discrimination 
assay using primers (Life Technologies) and allele-specific probes (PE 
Biosystems) as described previously.27  
Patients were divided in 4 groups based on their CCR532 genotype and 
hsCRP level: CCR5 ins/ins with low hsCRP (<10 mg/l), CCR5 ins/ins with 
high hsCRP (>10 mg/l), CCR532 with low hsCRP (<10 mg/l) and CCR532 
with high hsCRP level (>10 mg/l). Patients homo- or heterozygous for the 
deletion-allele were clustered since the presence of one minor allele has 
been associated with reduced receptor function.14 Causes of death were 
classified according to the codes of the European Renal Association – 
European Dialysis and Transplantation Association (ERA-EDTA).28 The 
following codes were used to classify cardiovascular mortality: myocardial 
ischemia and infarction; cardiac failure, fluid overload and pulmonary 
oedema; cardiac arrest; cerebro-vascular accident; haemorrhage from 
ruptured vascular aneurysm; mesenteric infarction; hyperkalaemia; 
hypokalaemia; cause of death uncertain or unknown.  
Analytical approach 
We modelled the potential cost-effectiveness of CCR5Δ32 screening and 
pharmacological CCR5 blockade using a decision-analytic Markov model 
(Figure 1). Markovian modelling is a commonly used technique in decision 
analyses to handle the complexity of multiple interconnective possible 
consequences.29 The health states in our Markov model were hemodialysis 
(HD), peritoneal dialysis (PD), renal transplantation (Tx) and death. Cohorts 
of 1000 patients entered the model in the HD or PD health-state and were 
followed for a time period of 10 years.  
 Figure 1: Decision tree and Markov model (M). Transition probabilities of the Markov 
model are shown in table 2. 
 
Clinical data were used to model transition probabilities; patients could 
receive a kidney transplant, experience renal graft failure and return to 
dialysis or die. The number of patients in each health state was determined 
by monthly cycles throughout the entire follow up period.30  
Effectiveness of pharmacological CCR5 blockade 
Transition probabilities for kidney transplantation and mortality were 
calculated using the patient level NECOSAD data.19 Kidney transplantation 
and mortality rates were calculated for the four patient groups. Because of 
small numbers the rate of renal transplant failure was calculated for all four 
groups combined. Pharmacological CCR5 blockade was assumed to mimic 
the effects of the Δ32 polymorphism in subjects with high inflammation 
status, thus improving patient survival in the patient group with the CCR5 
ins/ins genotype and systemic inflammation up to the level of the patient 
group with the CCR5Δ32 polymorphism and systemic inflammation. In 
particular, the relative risk (RR) for pharmacological CCR5 blockade in the 
inflamed group was calculated using clinical data as 0.61 for all-cause 
mortality, 0.41 for cardiovascular mortality and 0.80 for non-cardiovascular 
mortality. While the main focus of the current analysis was on mortality, we 
also calculated, based on clinical data, that pharmacological CCR5 blockade 





main focus on mortality we performed a separate analysis without modelling 
an effect on the probability of renal transplantation. 
Utilities 
Health-related quality of life (QoL) of patients on haemodialysis (HD) and 
peritoneal dialysis (PD) were obtained by interviewing patients participating 
in the NECOSAD study, detailed inclusion criteria and methods are 
described elsewhere.31 QoL of patients in the Dutch NECOSAD study were 
assessed with the EQ-5D instrument, which were applied to data from a UK 
population sample to obtain community based preference data.32 No QoL-
assessment of transplanted patients was performed in NECOSAD patients; 
these utilities were obtained from a Swedish study.33 With QoL 
measurements, cost-effectiveness estimations can be made in terms of 
costs per Quality-adjusted Life-years (QALY) gained. A commonly cited 
implicit thresholds for treatments that are deemed good value for money is 
€50,000 per QALY in The Netherlands.34  
Costs 
A third-party health-care payer perspective was adopted for cost estimates. 
Health-care costs were classified into one of two categories: related costs 
and unrelated future costs.35  
Related costs comprise costs directly related to the strategy under 
consideration. The cost of the genetic screening test for the CCR5Δ32 
polymorphism was based on polymerase chain reaction and included staff 
costs.36 The price of hsCRP screening was based on Dutch laboratory 
prices. Drug costs of pharmacological CCR5 blockade were based on Dutch 
prices of the CCR5 antagonist Maraviroc 300 mg (Celsentri) once daily,37 
including 6% value-added tax and a three-monthly pharmacists’ prescription 
fee of €6,00. Costs of cardiovascular mortality were based on national Dutch 
life tables and health-care expenditures adjusted for comorbidities.38 Costs 
of non-cardiovascular death and of transplantation graft failure were derived 
from a study with data from Dutch registries on renal diseases.39  
Unrelated future costs comprised costs that are independent of current 
spending, apart from the effects of that spending on survival.40, 41 In 
particular, as dialysis and renal transplantation care are not a direct 
consequence of CCR5 blockade but of the preexisting condition of end-
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stage renal disease; these costs were consistently classified as unrelated 
future costs. The costs of dialysis and renal transplantation were based on 
data on volumes of recourse use, including consultations, hospitalisations 
and laboratory services and use of medication obtained from the NECOSAD 
study.31  
In line with current pharmacoeconomic guidelines, unrelated future costs 
were not included.35, 42 However, to determine the influence of unrelated 
future costs, these costs were included in a separate analysis. All costs were 
updated to 2009 values. 
Discounting rates 
Costs were discounted at 4% per annum and health effects at 1.5% per 
annum, following Dutch guidelines for pharmacoeconomic research.43  
Sensitivity analyses 
Univariate and probabilistic sensitivity analyses and a threshold analysis 
were performed. In the univariate sensitivity analysis, all model parameters 
were varied by 25% in order to determine the main cost and effect drivers in 
our model. Discount rates were varied to 0% and 3% per annum based on 
recommendations by Gold et al and Drummond et al.44 The probabilistic 
sensitivity analysis was performed according to standard methods,29 using 
10,000 iterations and included all model parameters, except therapy costs 
and effectiveness of pharmacological CCR5 blockade which were explored 
in a threshold analysis. Gamma distributions were assumed for costs and 
beta distributions for utilities.29 In the absence of data on standard deviations 
for costs, we assumed 25% of the mean. Uncertainty in mortality and 
transplantation rates was captured by nonparametric bootstrapping of the 
NECOSAD data, using 10,000 iterations.45 As equivalence between genetic 
effects and associated pharmacologic effectiveness is not a given fact,46 a 
threshold analysis was performed to determine the combined influence of 
drug effectiveness and treatment costs of pharmacological CCR5 blockade 
on the cost-effectiveness of the screen-and-treat strategy. The 
pharmacoeconomic model and sensitivity analyses were constructed using 
the statistical package R, version 2.5.1. A graph of the threshold analysis 
was constructed using Sigmaplot version 10.0. 
Results 
Study population 
The study population used for modeling consisted of 413 patients. The 
CCR5 ins32/del32 polymorphism was distributed as follows: ins/ins: 333 
(80.6%); ins/del: 73 (17.7%) and del/del: 7 (1.7%). The genotype distribution 
did not deviate significantly from Hardy-Weinberg equilibrium (p=0.21). 
Baseline characteristics are shown in Table 1. The patient characteristics for 
the different genotype groups were similar at the start of dialysis, except 
antihypertensive medication use. Patients homo- or heterozygous for the 
deletion allele used more antihypertensive medications (p=0.01). From the 
413 patients included, 225 (55%) had the CCR5 ins/ins genotype and low 
hsCRP levels, 108 (26%) the CCR5 ins/ins genotype and high hsCRP 
levels, 55 (13%) the CCR5Δ32 polymorphism and low hsCRP levels and 25 
(6%) the CCR5Δ32 polymorphism and high hsCRP levels. 
 




Gender: male 253 (61.3) 
Age (year)  62 (50-71) 





Primary kidney disease 
   Diabetes mellitus 
   Glomerulonephritis 
   Renal vascular disease 






Cardiovascular disease 144 (34.9) 
Diabetes mellitus 105 (25.4) 
Smoking 
   Never 
   Former 





DBP (mmHg) 83 (12.8) 
SBP (mmHg)  150 (25.4) 
Antihypertensive medication 356 (86.2) 
Lipid lowering medication 121 (29.3) 
hsCRP (mg/l)   
hsCRP > 10 (mg/l)     
5.1 (1.9-13.7) 
133 (32.2) 
Cholesterol (mmol/l) 5.0 (1.3) 
Albumin (g/l)  32.5 (6.9) 
Hemoglobin (g/dl) 11.0 (1.4) 
GFR (ml/min) 4.2 (3.1) 




Mortality and transplantation rates 
Annual transition probabilities without CCR5 antagonist therapy are shown in 
Table 2. The probability of renal transplantation was lower in the patient 
group with CCR5 ins/ins genotype and systemic inflammation compared to 
the three other patient groups. Cardiovascular and non-cardiovascular 
mortality was higher in the patient group with CCR5 ins/ins genotype and 
systemic inflammation compared to the other patient groups. In the Markov 
model, pharmacological CCR5 blockade in this patient group improved 
survival and the probability of renal transplantation up to the level of patients 
with the CCR5Δ32 polymorphism and systemic inflammation (Table 2). 
Cost-effectiveness 
Parameters used for the analyses are shown in Table 3. Screening for the 
CCR5Δ32 polymorphism and treating patients with the CCR5 ins/ins 
genotype and systemic inflammation with pharmacological CCR5 blockade 
resulted in an average of 0.36 life years and 0.31 QALYs gained at an 
expense of €8,482 per patient compared to €1,863 per patient in the non-
screening cohort (Table 4). Therefore, the incremental cost-effectiveness 
ratio (ICER) of the screen-and-treat strategy compared to not screening was 
€18,557 per life-year gained (LYG) and €21,896 per QALY gained. Results 
were similar without the model assumption that pharmacological CCR5 
blockade improved patients’ probability of renal transplantation, €18,494 per 
LYG and €24,642 per QALY gained. 
As described, the unrelated future costs of dialysis and transplantation care 
due to improved survival were not included. The aforementioned increased 
survival of 0.36 life years in the genetically screened cohort indeed required 
considerable dialysis costs. These costs were only partly offset by a shift 
towards less costly renal transplantation care in these patients. In total, 
additional unrelated future costs were €6,720 per patient in the screening 
cohort. When these costs are included, the cost-effectiveness of the 
selective screen-and-treat strategy rose considerably to €37,400 per LYG 
and €44,127 per QALY gained, thus doubling the ICERs for these scenarios. 
 
Table 2: Annual transition probabilities (95% CI) in the four CCR5Δ32 polymorphism 



























































* In the genotyping strategy of the economic model, patients with the CCR5 ins/ins 
and high inflammation status received CCR5 antagonists; thereby increasing 
transplantation rates and reducing mortality rates up to the level of patients with the 





Table 4: Cost-effectiveness in the base-case analysis 
 
  Costs Life years QALY 
Standard care € 1,863 5.71 4.36 
Screen-and-treat strategy €8,482 6.07 4.67 
Screen-and-treat strategy (no Tx effect) €8,460 6.07 4.63 
 
Cost-effectiveness  Cost per LYG 
Cost per QALY 
gained 
Screen-and-treat strategy €18,557 €21,896 
Screen-and-treat strategy (no Tx effect) €18,494 €24,642 
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Table 3: Parameters used in the analyses 
 
 
Variable Baseline value ± SD Reference 
Costs   
Discounting rate for costs 4% 43, 63  
Related costs *   
     Genetic screening test  €50 ± 13 36  
     CRP screening test  €21 ± 5  
     Drug costs Maraviroc (per year)  €5,057 ± 1,264 37 
     Transplantation graft failure €4,581 ± 1,145 39  
     Cause of death   
          Myocardial ischemia and infarction €2,448 ± 612 38  
          Cardiac failure/ fluid overload/ pulmonary oedema €4,529 ± 1,132 38  
          Cardiac arrest €2,448 ± 612 38  
          Cerebro-vascular accident €5,753 ± 1,438 38  
          Mesenteric infarction €3,550 ± 888 38  
          Hyperkalaemia €1,224 ± 306 38  
          Cause unknown or cause uncertain ** €3,469 ± 867 38  
          Non-cardiovascular mortality  €2,316 ± 579 39  
Unrelated future costs *   
     ESRD care costs   
          Hemodialysis year 1  €84,825 ± 21,206 31  
          Hemodialysis later years  €80,482 ± 20,121 31  
          Peritoneal dialysis year 1  €65,706 ± 16,427 31  
          Peritoneal dialysis later years  €60,985 ± 15,246 31  
          Transplantation year 1  €52,199 ± 13,049 31  




Discounting rate for health effects 1.5% 43, 63 
Quality of Life   
     Hemodialysis 0.71 ± 0.275 31  
     Peritoneal dialysis 0.75 ± 0.256 31  
     Transplantation 0.86 ± 0.133 33  
Mortality and transplantation probabilities See table 1 19  
Therapy effectiveness (Relative Risk)    
     All-cause mortality 0.61 19  
     Cardiovascular mortality 0.41 19  
     Non-cardiovascular mortality 0.80 19  
     Renal transplantation 2.41 19  
* In the absence of data on standard deviations for costs, we assumed 25% of the 
mean.  





Sensitivity & threshold analyses 
Results of the probabilistic sensitivity analysis are shown in Figure 2, 
demonstrating the uncertainty around the cost-effectiveness estimates of the 
screen-and-treat strategy. The increase in cost-effectiveness as well as the 
uncertainty around these estimates due to including unrelated future costs is 
evident. In Figure 2, the solid dot denotes the base-case outcome (using the 
most likely parameter estimates) while the inner and outer ellipses denote 
the 50% and 90% probability intervals, respectively, around this base-case 
estimate. Univariate sensitivity analyses showed that the main drivers of the 
cost-effectiveness of the screen-and-treat strategy were the costs of 
pharmacological CCR5 blockade and the effectiveness of pharmacological 
CCR5 blockers to reduce mortality. The cost-effectiveness was relatively 
insensitive to plausible variations of the other parameters. These two main 
parameters were further explored in a threshold analysis, shown in Figure 3. 
The red line in this figure denotes the base-case assumptions for drug 
effectiveness and treatment costs. With decreasing therapy costs and 
increasing therapy effectiveness, cost-effectiveness of the screen-and-treat 
strategy improved. With the costs of pharmacological CCR5 blockade at the 
base-case level of €5,057 per year or €421 per month, a RR for all-cause 
mortality of 0.82 or lower would cause the cost-effectiveness of the screen-
and-treat strategy to be €50.000 or less per QALY gained. If the costs of 
CCR5 blockers drop, even a modest effectiveness in reducing inflammation-
driven mortality would result in a treatment strategy that is good value for 
money. 
       
Figure 2a and b: Cost-effectiveness of the screen-and-treat strategy. Figure a (left 
panel): excluding unrelated future costs (ESRD-care costs). Figure b (right panel): 
including unrelated future costs. Dotted line denotes the willingness-to-pay threshold 





Figure 3: Threshold analysis on the influence of CCR5 blocking therapy costs and 
effectiveness on the cost-effectiveness of a screen-and-treat strategy. The red lines 




Our study analyzed the potential cost-effectiveness of screening for the 
CCR5Δ32 polymorphism and selectively treating dialysis patients with the 
CCR5 ins/ins genotype and systemic inflammation with pharmacological 
CCR5 blockers. It was shown that such a strategy could be incorporated in a 
potentially cost-effective genetic screen-and-treat program. 
Observational studies in which a genetic polymorphism is associated with a 
well-characterized functional phenotype can be considered as a type of 
clinical trial, with randomization at conception, referred to as Mendelian 
randomization.4-6 Following this approach, we investigated the presumption 
that in an analogous manner, pharmacological CCR5 blockade could lead to 
better survival in ESRD patients and estimated the cost-effectiveness of a 
genetic screen-and-treat strategy based on this strategy. We used data from 
a genetic association study in ESRD patients. In this study an association 
with better survival was found in incident dialysis patients with systemic 
inflammation carrying the CCR5∆32 genotype, which was replicated in a 
Swedish ESRD cohort, hereby showing the robustness of these findings. 
Moreover, since the number of patients in the CCR532 groups was small, 
we did in the previous study an analysis on the two cohorts combined, 
leading to the same results.19 The presence of the CCR5∆32 polymorphism, 
leading to a less functional receptor,14 was used as a naturalistic form of 
pharmacologically blocking the CC-chemokine 5 receptor. This approach 
was used recently in Cholesterol Ester Transfer Protein (CETP) inhibition, 
identifying alleles which lead to reduced CETP levels and activity.47 Other 
cost-effectiveness assessments of potential pharmacologic interventions 
have previously been performed, for example in cardiovascular disease and 
polypill therapy.48 Considering the ACCE (analytic validity, clinical validity, 
clinical utility and ethical, legal and social issues) model framework for 
enhancing the evaluation of genetic tests, our study adds to the second C by 
providing cost-effectiveness data that supports clinical utility.49, 50 
A long-standing controversy in health-economics is whether unrelated future 
costs should be included in cost-effectiveness analyses.40, 41, 51, 52 Dialysis 
treatment is expensive and associated with a high cost per QALY gained.31, 
53 As dialysis is required lifelong, the cost-effectiveness of therapies in ESRD 
patients have been said to be driven more by dialysis costs than by the costs 
and benefits of the intervention under consideration itself.54 Our analysis 
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confirms these earlier findings and underscores the relevance of the debate 
by calculating that inclusion of dialysis and renal transplant care costs 
doubles the incremental cost-effectiveness ratio of the screen-and-treat 
strategy. Several studies in ESRD patients did not include the future costs of 
ESRD-care,55-57 while others analysed therapies both with and without future 
costs.58-60 By excluding ESRD-costs in the main analysis but including them 
in a separate analysis our results can be widely compared. The cost-
effectiveness with inclusion of future ESRD-costs were comparable to other 
studies focusing on systemic anticoagulation,60  hyperphosphataemia,59 
secondary hyperparathyroidism,58 and anaemia.61  
In addition to adherence to guidelines for pharmacoeconomic research as 
possible within the constraints of novel pharmacogenetic screening 
programs,22 the present study had two major strengths: 1. the analyses 
considered hard end points, mortality and renal transplantation;  2. most 
primary data used in the pharmacoeconomic analysis, such as costs, quality 
of life estimates and efficacy data, were derived from a single prospectively 
followed dialysis cohort (NECOSAD). These strengths enhanced the clinical 
relevance and analytical robustness of the study findings. Although cost data 
used in our study were specific for the Netherlands, chronic kidney disease 
(CKD) care costs such as dialysis costs have been reported to fall within a 
narrow range despite considerable variation in country of study, 
methodology and imputed costs.53 Country specific variations in drug costs 
and discounting rates have been accounted for in sensitivity analyses.  
An important aspect of our study is the notion that equivalence between 
genetic effects and associated pharmacologic effectiveness is not a given 
fact. For example, a discordance has been described between the genetic 
effect of familial hypercholesterolaemia and the effectiveness of statin 
treatment on cardiovascular mortality.46 The explanation for this discrepancy 
lies in the fact that genetic factors, as opposed to pharmacologic 
interventions, cause life-long differences in risk factors.46 Genetic factors are 
also not affected by traditional sources of uncertainty in clinical 
effectiveness, such as therapy compliance. Indeed, sensitivity analyses 
showed that the cost-effectiveness was highly influenced by the 
concordance between the genetic association and pharmacological 
effectiveness. Still, while the true effectiveness of pharmacological CCR5 
blockade in ESRD patients on mortality is not (yet) known, this study, in 
particular the threshold analysis, provides valuable information for future 
108 
 
clinical trials in this field. In this context, the threshold analysis showed that 
even modest pharmacological effectiveness would result in a treatment 
strategy that is good value for money. A similar approach has recently been 
taken in analyzing the potential cost-effectiveness of alternative treatments 
for CKD patients resistant to ACE inhibitors due to ACE (I/D) 
polymorphisms.36 Finally, the robustness of the cost-effectiveness estimate 
depends on whether or not pharmacologically blocking CCR5 is safe in 
ESRD patients. However, treating HIV-infected ESRD patients with a CCR5 
antagonist seemed safe and no dose adjustments were necessary.62 The 
next research step could be conducting an observational cohort study in 
HIV-infected ESRD patients, to compare cardiovascular morbidity or 
mortality or surrogate endpoints such as intima media thickness, among 
users and non-users of CCR5 blocker therapy.  
In conclusion, we evaluated the potential cost-effectiveness of 
pharmacologically blocking the CCR5 receptor in inflamed dialysis patient 
with the CCR5 ins/ins genotype, and found it to be similar to existing 
treatment modalities for dialysis patients. Recently CCR5 blockade has 
indeed become feasible in humans. Our data suggest that, from an 
economic point of view, it would be worthwhile to study whether 
pharmacological blockade of CCR5 has therapeutic and economical benefits 
in dialysis patients with persistent inflammation. Our study is an illustration of 
the potential of genetic studies in drug-development programs, as a new 
source of Mendelian randomized evidence from an observational setting. 
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In end stage renal disease (ESRD) and type 2 diabetes atherosclerosis and 
chronic inflammation are important factors in the high morbidity and mortality 
seen in these populations.1-7 Since therapies proven to be successful in the 
general population have thus far been disappointing in patients with ESRD,8-
10 and since atherosclerosis is nowadays considered a chronic inflammatory 
disease,11, 12 the inflammatory process is an area of increased interest in 
these patients.  
In this process of inflammation and atherosclerosis chemokines play an 
important role.13, 14 Chemokines can be classified into four major categories 
(C, CC, CXC and CX3C). The CC chemokines and their receptors have 
been widely implicated in atherosclerosis.15, 16 Among these, the CC-
chemokine receptor 5 (CCR5) is expressed on T cells, monocytes/ 
macrophages, smooth muscle cells and endothelial cells.17, 18 These cells 
are involved in the chronic inflammatory state present in insulin resistance, 
type 2 diabetes, atherosclerosis and uremia.3, 7, 11, 19 Several polymorphisms 
have been described for CCR5. The CCR5∆32 genetic variant is located on 
the chromosome 3p21 and consists of a 32-basepair deletion in the open 
reading frame. It effectively results in functional CCR5 deficiency by absence 
of CCR5 membrane expression.20 Different human association studies 
showed that CCR5∆32 is associated with better outcome in patients with a 
high risk for atherosclerotic cardiovascular disease, and in renal transplant 
recipients, probably by modulation of the inflammatory response in these 
conditions.21-24 In animal studies using mouse models the role of CCR5 has 
been verified by both pharmacological receptor antagonism and genetic 
deletion.25-34 The mechanisms by which CCR5 and CCR5 deficiency 
contribute to chronic inflammation and atherosclerosis are believed to be 
due to their effects on immune cell migration and response.14, 35 Notably, in 
mice CCR5 deficiency was associated with a reduction in Th1 type immune 
response.25, 28 Moreover, in animal models CCR5 deficiency modulates 
monocyte recruitment in atherosclerotic lesions and is associated with 
improved plaque stability.14, 16, 27  
Taken together, these data suggest that CCR5 might be involved in the 
accelerated atherosclerosis in chronic inflammatory conditions like ESRD 
and type 2 diabetes. Substantiation of this role would be clinically relevant, 
as CCR5 might provide a novel target for intervention, with, moreover, also 
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practical feasibility as pharmacological blockers of CCR5 are already 
available and in use in anti-HIV therapy.36  
The studies in this thesis therefore, were aimed at exploring the possible role 
of CCR5 in the increased (cardiovascular) mortality in the chronic 
inflammatory, atherosclerotic conditions of ESRD and type 2 diabetes, and 
at exploring its potential as a possible target for intervention. 
 
In chapter 2 we demonstrated that the presence of CCR5∆32 is associated 
with better survival in patients with type 2 diabetes.37 These data are in line 
with the impact of the CCR532 in several other populations as mentioned 
above. The protective effect of the CCR532 is allegedly due to a 
dysfunctional CCR5 leading to modulation of inflammatory responses. 
Unfortunately, in this population we had no data available on the severity of 
the inflammatory state or on possible differences in inflammatory pathways 
between the genotypes to support such a mechanism of protection.  
In ESRD CRP is associated with overall and cardiovascular mortality, 
demonstrating the impact of inflammation on outcome in this high risk 
population.38 In chapter 3 we demonstrated that the CCR532 genotype 
attenuates the adverse effects of an inflammatory state on overall and 
cardiovascular mortality in ESRD, in two independent cohorts of patients 
with ESRD, from the Netherlands and Sweden.39 These data support the 
clinical impact of a gene-environment interaction, the inflammatory state 
being the environmental factor with an adverse effect on outcome, that is 
however blunted by the genetic factor CCR532, possibly by genetically 
mediated CCR5 deficiency. Support for such a mechanism is provided in 
chapters 4 and 5. In chapter 4 we report on a reduced Th1 type immune 
response as represented by decreased TNF-α levels in patients with ESRD 
carrying the CCR532 genotype as compared to non-carriers.40 In chapter 5, 
subsequently, we describe for the first time in a functional, human study the 
possible modifying effect of the CCR532 genotype on the Th1/Th2 
disequilibrium of atherosclerotic inflammation. Stimulated CD4+ and CD8+ T 
cells of patients with one or two CCR5∆32 alleles show an increased Th2 
type phenotype base on their intracellular cytokine profile. These differences 
in immune response may be involved in the impact of CCR5∆32 on outcome 
in ESRD.  
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As these data support the relevance of CCR5 as a novel target for 
intervention in the chronic inflammatory process in ESRD, in chapter 6 we 
performed a simulation study on the potential cost-effectiveness of 
CCR5Δ32 screening and pharmacological CCR5 blockade in dialysis 
patients. In this study we used the documented effects of genetically 
determined CCR5 deficiency in ESRD to estimate the clinical benefits of 
pharmacological CCR5 blockade in this population. This estimate was used 
for a pharmaco-economic analysis on the effects of pharmacological CCR5 
blockade in ESRD. Based on this simulation study we conclude that, from an 
economic point of view, it would be worthwhile to study whether 
pharmacological blockade of CCR5 has therapeutic and economical benefits 
in dialysis patients with persistent inflammation and the CCR5 ins/ins 
genotype. This study is an illustration of the potential of genetic studies in 
drug-development programs, as a new source of Mendelian randomized 
evidence from an observational setting.41 
 
The studies described in this thesis show that CCR5 is of importance in the 
chronic inflammatory, atherosclerotic process seen in patients with type 2 
diabetes and in patients with ESRD and that chemokine pathways, 
especially CCR5 could be a novel target for intervention that could 
theoretically have considerable impact on outcome. Our data show, that in 
patients with ESRD with chronic inflammation a dysfunctional CCR5 reduced 
the annual probability on mortality from approximately 10% to 5%.39, 41 
Whereas, obviously, these figures should not straightforwardly be 
extrapolated to the results of a pharmacological intervention, nevertheless, it 
is clear that the contribution of CCR5 in the mortality in this patient group, 
and hence its potential as a target for intervention, is substantial.   
Several animal studies using mouse models suggested a role for blockade 
of the CCR5 pathway as a therapy in atherosclerotic, inflammatory 
conditions.29-31 To date, only one small molecule antagonist of CCR5, 
Maraviroc, has cleared the many hurdles needed to permit licensing for 
clinical usage and is used in the treatment of HIV infection.36, 42 For 
cardiovascular or other inflammatory diseases no human, intervention 
studies are available. The reason for this most likely is the complexity of the 
role of chemokines and chemokine receptors in the inflammatory process 
seen in cardiovascular disease.   
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At present, the chemokine system consists of 50 chemokines and more than 
19 chemokine receptors. They play a role in the multistep leucocyte 
adhesion cascade and they regulate a wide range of processes.43 A 
characteristic of the majority of chemokine receptors is their high affinity for 
multiple ligands. This implies that the same ligand can cause different 
biological effects depending on the type of chemokine receptor expressed 
on target cells.35, 44 Also, depending on the anatomical site or the 
physiological circumstances chemokines can act differently and they display 
a considerable synergy.13, 44 Recently it was demonstrated that chemokines 
are able to form oligomeric structures, mainly dimers and that the biological 
effect depends on the oligomerization.13, 44 This all leads to the notion that 
the activity of chemokines can be specific to a distinct cell type, site and/or 
phase in plaque progression. For example, CCR5 is thought to be more 
important in the late stages of plaque development.25, 27  
Interfering in the CCL2/CCR2, CCL5/CCR5, CX3CL1/CX3CR1, 
CXCL8/CXCR2 pathways could provide promising therapeutic targets for 
atherosclerotic disease, as supported by different animal models.44 When 
focussing on CCR5 ligands several mouse and human tissue studies 
underscore a link with atherosclerotic disease. For example, knock-down of 
CCL5 expression on vascular smooth muscle reduces neointimal thickening 
and macrophage infiltration in ApoE-/- mouse models;45 blocking CCL5 
function was found to lessen progression of atherosclerotic plaque in LDLr-/- 
mice;26 disruption of CCL5 and platelet factor PF-4 led to a reduction in 
atherosclerotic lesions in hyperlipidemic mice;46 Expression of CCL3, CCL4 
and CCL5 has been detected in human arteries and atherosclerotic 
plaques.17, 47, 48   
Taking into account the specific effects of the different chemokines and 
chemokine receptors in the atherogenic cell recruitment, the potential role of 
blocking multiple components of the chemokine system simultaneously for 
prevention and treatment of atherosclerosis has been advocated. For 
example, targeting three chemokine-receptor systems, CCL2/CCR2, 
CCL5/CCR5, CX3CL1/CX3CR1, could be a promising strategy.33, 49  
Possible adverse effects of chemokine intervention for prevention and 
therapy of atherosclerosis have to be considered as well. Because the 
chemokine system is an integral part of the immune system shutting down it 
constituents might be accompanied by an increased risk of unwanted 
immunological side effects. For example, CCR5∆32 seem to be associated 
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with infection with the West Nile virus and tickborne encephalitis.50, 51 
Moreover, considering the nature of atherosclerosis as a chronic 
inflammatory condition, tolerability and safety issues related to long term use 
should be addressed. Delivering tailored therapy to the patient categories 
likely to benefit most could be a way to favourable affect the risk-benefit ratio 
of treatment. Based on our results, for instance, it would be logical to take 
into account inflammatory status, and genotype of the patient. In ESRD the 
category likely to benefit from CCR5 blockade, accordingly, would be 
patients with the CCR5 ins/ins genotype and signs of systemic 
inflammation.39, 41  
In conclusion, a significant amount of evidence can be found supporting the 
therapeutic potential of certain chemokine-chemokine receptor blockade. 
Given the fact that CCR5 seems to play a crucial role in cardiovascular 
disease and given the fact that Maraviroc is currently the only 
pharmacological chemokine blocker available as a clinically validated drug 
on the market, albeit for a completely different condition, provides a 
significant advantage for targeting CCR5 over the other chemokine-
receptors. However, numerous issues should be resolved. Given the high 
risk for cardiovascular disease in patients with HIV-infection,52 it could be 
fruitful, in this respect, to systematically document inflammatory status and 






Current therapy in cardiovascular disease in the general population and in 
high risk populations like type 2 diabetes and ESRD has mainly targeted 
classical risk factors such as elevated blood presssure and lipid levels, and 
smoking. More recently, proteinuria has become a target for intervention as 
well. Although this strategy is generally effective, there remains an urgent 
need for innovative therapeutic approaches, in particular in high-risk groups 
such as ESRD and type 2 diabetes, as apparently, current therapy fails to 
reduce the excessively high risk for atherosclerotic complications in these 
conditions. Given the extensive role of the innate and adaptive immune 
responses in atherosclerosis, targeting its cellular constituents seems a 
valuable approach for attenuating the disease process. As systemic 
modulation of immune responses can severely compromise host defence, a 
dissection of the cellular mechanisms that are involved in atherogenesis will 
allow targeted interventions that might minimize the unwanted effects of 
broad-spectrum treatments. Because chemokines and their receptors are 
key mediators in the immune response seen in atherogenesis, targeting 
these pathways is promising. However, the precise mechanism of the 
different chemokine pathways in the establishment and progression of 
atherosclerotic disease and the therapeutic potential of blocking chemokine 
pathways have yet to be elucidated. In this complex process multiple gene-
environmental interactions play an important role. Genetic association 
studies can be used to discover new pathways, and indicate their impact on 
the burden of disease in human populations. The associations should lead to 
further mechanistic studies both in animal and human models. Eventually 
randomized controlled trials with hard end points in well-defined patient 
populations are needed. To facilitate this expensive and time consuming 
process, genetic differences between persons leading to well characterized 
functional phenotypes can be used as a heuristic strategy to explore 
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Ondanks grote vooruitgang in de behandeling van hart- en vaatziekten door 
behandeling van risicofactoren zoals hypertensie en hypercholesterolemie 
blijven cardiovasculaire ziekten een belangrijke oorzaak van ziekte en 
overlijden wereldwijd. Met name ook bij patiënten met diabetes mellitus type 
2 en bij patiënten met eindstadium nierfalen zijn cardiovasculaire 
aandoeningen veel voorkomend. In deze laatste groep speelt nog mee dat 
behandelingen die succesvol zijn gebleken in de algemene populatie, zoals 
bijvoorbeeld cholesterol verlaging, minder succesvol zijn. Dit onderstreept 
het belang van het verder ontrafelen van het onderliggende 
pathofysiologische proces van hart- en vaatziekten, speciaal bij patiënten 
met eindstadium nierfalen om uiteindelijk nieuwe therapieën te ontwikkelen. 
Tegenwoordig wordt het onderliggende proces van hart- en vaatziekten 
gezien als een ontstekingsreactie. Aan het begin van dit proces, ook wel 
bekend als het 'response to injury proces', is er sprake van activatie en 
dysfunctie van endotheelcellen in de bloedvaten. Deze cellen raken 
geactiveerd door omgevingsfactoren. Ook genetische factoren spelen hierbij 
een rol in een zogenaamde gen-omgeving interactie. De endotheel-
dysfunctie geeft aanleiding tot vorming van adhesie-moleculen, vrijkomen 
van chemokinen en cytokinen en influx van ontstekingscellen zoals 
monocyten, T-cellen en andere ontstekingscellen in de subendotheliale 
ruimte. Als gevolg van deze ontstekingsreactie in de subendotheliale ruimte 
ontstaat allereerst een zogenaamde ‘fatty streak’. Verdere ontsteking leidt 
tot de ontwikkeling van atherosclerotische plaques. Deze plaques kunnen 
uiteindelijk leiden tot klinische symptomen door bijvoorbeeld 
bloedvatvernauwing of afsluiting. 
Bij de onderliggende ontstekingsreactie kan men onderscheid maken in de 
aangeboren immuunreactie waarbij monocyten/ macrofagen, natural killer T-
cellen en dendritische cellen een rol spelen en specifieke afweer waarbij B- 
en antigeen specifieke T-cellen een rol spelen. Verschillende subklassen 
van T-cellen zijn hierbij van belang. Dit zijn voornamelijk CD4+ T-cellen en in 
mindere mate CD8+ T-cellen. De CD4+ T-cellen kunnen differentiëren in T-
helper 1 (Th1) cellen, T-helper 2 (Th2) cellen, T-helper 17 (Th17) cellen en 
regulatoire T-cellen. Th1 cellen produceren interferon gamma (IFN-) als 
belangrijkste cytokine. Activatie van Th1 cellen leidt tot tumor necrose factor 
alpha (TNF-α) secretie. De Th1 type immuunreactie wordt beschouwd als 
pro-inflammatoir en pro-atherogeen. Van Th2 cellen en de cytokinen, 
interleukine 4 (IL-4), interleukine 5 (IL-5) en interleukine 10 (IL-10), wordt 
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aangenomen dat ze, in ieder geval deels, een anti-inflammatoire en anti-
atherogene rol spelen. 
In dit ontstekingsproces spelen ook chemokinen een belangrijke rol. 
Chemokinen binden aan chemokine-receptoren, die aanwezig zijn op 
ontstekingscellen zoals T-cellen, monocyten/ macrofagen en spelen een rol 
bij de verplaatsing van deze cellen naar ontstekingsgebieden. In 
muizenstudies is gebleken dat uit de grote chemokine familie voornamelijk 
de CC-chemokinen en hun receptoren betrokken zijn bij atherosclerose. Een 
van deze CC-chemokine-receptoren is de CC-chemokine 5 receptor 
(CCR5). Van deze chemokine-receptor zijn verschillende genetische 
varianten bekend waaronder het zogenaamde CCR5∆32 polymorfisme. 
Deze variant leidt uiteindelijk tot CCR5 deficiëntie door afwezigheid van 
expressie aan het celoppervlak bij homozygoten en verminderde expressie 
bij heterozygoten. In de Europese populatie is ongeveer 15% heterozygoot 
en 1-2% homozygoot voor deze genetische variant. Bij HIV-positieve 
patiënten is aangetoond dat CCR5∆32 geassocieerd is met resistentie tegen 
infectie met HIV hetgeen aantoont dat de mutatie inderdaad tot functionele 
veranderingen leidt. Verder werd in patiëntengroepen met een hoog risico 
op hart- en vaatziekten de CCR5∆32 mutatie geassocieerd met een betere 
uitkomst, hoewel hier ook tegenstrijdige berichten over zijn. Als verklaring 
voor deze gunstige effecten van de aanwezigheid van CCR5∆32 wordt 
gedacht aan een modulatie van de immuunreactie. In muizen lijkt CCR5 
deficiëntie tot een verminderde Th1 type immuunreactie te leiden en is 
sprake van een meer stabiele atherosclerotische plaque. 
Deze zaken bij elkaar opgeteld, samen met het feit dat er bij patiënten met 
eindstadium nierfalen sprake is van een chronische ontstekingsreactie, 
maken dat CCR5 mogelijk een geschikte kandidaat is om het 
ontstekingsproces, dat bij de nierpatiënt tot hart- en vaatziekten leidt, te 
beïnvloeden. Het interessante van CCR5 is dat er een geneesmiddel op de 
markt is dat CCR5 blokkeert. Dit geneesmiddel wordt gebruikt bij de 
behandeling van HIV-infectie. Door de beschikbaarheid van dit middel zijn er 
praktische mogelijkheden om te onderzoeken of CCR5 blokkade effect heeft 
op hart- en vaatziekten bij de mens. In dit proefschrift bespreken we daarom 
epidemiologische en functionele consequenties van CCR5∆32 in 




In het tweede hoofdstuk hebben we de hypothese getoetst of de 
aanwezigheid van CCR5∆32 bij patiënten met diabetes mellitus type 2 
geassocieerd is met overleving. We hebben hiervoor gebruik gemaakt van 
een cohort patiënten met diabetes mellitus type 2 uit de regio Zwolle 
(ZODIAC cohort) dat werd gevolgd gedurende een langere periode. De 
aanwezigheid van de CCR5∆32 genetische variant bleek gerelateerd te zijn 
aan betere overleving. We veronderstellen dat dit te maken heeft met 
verschillen in beloop van ontstekingsprocessen tussen patiënten met en 
zonder de CCR5∆32 variant. Echter omdat er in dit cohort geen gegevens 
beschikbaar waren over ontstekingsactiviteit konden we deze 
veronderstelling niet toetsen.   
In een volgende studie, bij patiënten met eindstadium nierfalen, was het wel 
mogelijk om de rol van  ontstekingsactiviteit mee te nemen. Bij deze 
patiënten was namelijk het C-reactive protein (CRP) gemeten. CRP is een 
marker van ontsteking; bij patiënten met eindstadium nierfalen is een 
verhoogd CRP geassocieerd met mortaliteit in het algemeen en 
cardiovasculaire mortaliteit hetgeen wijst op een belangrijke rol van 
ontstekingsactiviteit in de sterfte bij deze patiënten, in het bijzonder aan hart- 
en vaatziekten. Het zou zo kunnen zijn dat in dit ontstekingsproces een 
dysfunctionele CCR5 receptor een gunstige invloed heeft door verminderde 
migratie van ontstekingscellen. In het derde hoofdstuk hebben we daarom in 
een Nederlands en een Zweeds patiëntencohort met eindstadium nierfalen 
onderzocht of aanwezigheid van de CCR5∆32 genetische variant een 
dempend effect heeft op de relatie tussen een verhoogd CRP en overleving. 
Dit bleek inderdaad het geval te zijn; patiënten met de CCR5∆32 genetische 
variant en een verhoogd CRP hadden een vergelijkbare overlevingskans als 
patiënten zonder verhoogd CRP. Bij patiënten met een verhoogd CRP, 
zonder de CCR5∆32 genetische variant was de overleving significant 
slechter. Dit is een voorbeeld van een duidelijke gen-omgeving interactie: de 
genetische variant beschermt tegen de ongunstige effecten van ontsteking.  
In hoofdstuk 4 en 5 wordt gezocht naar de mechanismen van het 
beschermende effect. Hiervoor is het van belang om te weten dat pro-
inflammatoire cytokinen geassocieerd zijn met slechte uitkomst in patiënten 
met eindstadium nierfalen en dat een immuunreactie van het type Th1 en de 
bijbehorende cytokinen pro-atherogeen zijn, hetgeen betekent dat ze 
vaatschade kunnen veroorzaken. Uit muizenstudies is bekend, zoals boven 
reeds vermeld, dat CCR5 deficiëntie, zowel genetisch als door 
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farmacologische blokkade leidt tot een immuun respons met meer type Th2 
dan Th1 kenmerken zoals minder pro-inflammatoire cytokine productie. Om 
na te gaan of de CCR5∆32 variant gepaard gaat met minder cytokine 
release als reactie op ontsteking hebben we in een cohort patiënten met 
eindstadium nierfalen gekeken of de CRP, TNF-α, IL-6 en IL-10 spiegels 
verschilden in dragers en niet-dragers van de CCR5∆32 genetische variant. 
Het bleek inderdaad zo te zijn dat de TNF-α spiegels significant lager waren 
bij patiënten met aanwijzingen voor systemische ontsteking blijkend uit een 
verhoogd CRP als er sprake was van de CCR5∆32 genetische variant. In 
het vijfde hoofdstuk hebben we geprobeerd om de hypothese dat de 
CCR5∆32 genetische variant ertoe leidt dat de immuunreactie sterkere Th2 
dan Th1 kenmerken vertoont en daardoor vaatschade kan remmen verder te 
onderbouwen. Hiertoe stimuleerden we T-cellen van dragers en niet-dragers 
van de CCR5∆32 genetische variant met eindstadium nierfalen om zo de  
ontstekingsreactie na te bootsen. Vervolgens bepaalden we het 
intracellulaire cytokine profiel van deze cellen en vergeleken dit met elkaar. 
Hieruit bleek dat zowel CD4+ als CD8+ T-cellen van dragers van de 
CCR5∆32 genetische variant na stimulatie een meer uitgesproken Th2 type 
immuunreactie laten zien. Dit is de eerste maal dat bewezen wordt dat 
CCR5∆32 bij de mens effect heeft op de eigenschappen van de 
immuunrespons.  Deze ‘gunstige’ immuunreactie zou een verklaring kunnen 
zijn voor het beschermende effect van CCR5∆32 bij patiënten met 
eindstadium nierfalen.  
De ontwikkeling van nieuwe farmacologische therapieën is een kostbare 
aangelegenheid zowel in tijd als in geld. Om deze reden is er behoefte aan 
alternatieven om dit proces te vergemakkelijken. Observatiestudies, waarbij 
genetische varianten met een goed gekarakteriseerd, functioneel fenotype 
worden bestudeerd, zouden hierbij kunnen helpen. Dergelijke studies 
kunnen namelijk worden beschouwd als een 'real life' simulatie van een 
klinische trial met randomisatie bij de conceptie (ook wel aangeduid als 
'Mendeliaanse randomisatie'). Op grond van dit principe hebben we naar 
aanleiding van de bevindingen uit hoofdstuk 3 een simulatiestudie 
uitgevoerd naar de kosteneffectiviteit van screenen op aanwezigheid van 
CCR5∆32 en vervolgens farmacologisch blokkeren van de CCR5 receptor 
bij patiënten met eindstadium nierfalen. In deze studie toonden we aan dat 
het screenen op CCR5∆32 en het farmacologisch blokkeren van CCR5 
kosteneffectief is bij patiënten met eindstadium nierfalen. Deze studie is een 
137 
 
illustratie van de bruikbaarheid van genetische associatiestudies bij de 
ontwikkeling van nieuwe farmacologische therapieën. 
 
De studies in dit proefschrift onderstrepen het belang van CCR5 in het 
chronische ontstekingsproces dat leidt tot vaatschade bij patiënten met 
eindstadium nierfalen en ondersteunen de veronderstelling dat interventie in 
het chemokine systeem, speciaal blokkering van CCR5, een therapeutische 
optie zou kunnen zijn. Uit diverse muizenstudies waarbij gekeken werd naar 
vaatschade, is gebleken dat blokkade van CCR5 gunstige effecten heeft. 
Het is bemoedigend dat er voor humaan gebruik een CCR5 antagonist 
beschikbaar is, gebruikt als antiviraal middel bij HIV-positieve patiënten. Er 
zijn echter geen data voorhanden waarin dergelijke geneesmiddelen worden 
gebruikt ter bescherming tegen hart- en vaatziekten bij de mens. Een 
mogelijke oorzaak hiervoor is de zeer complexe rol die chemokinen en 
chemokine-receptoren spelen bij hart- en vaatziekten. Zo hebben 
chemokinen een hoge affiniteit voor verschillende receptoren: dit betekent 
dat een chemokine meerdere effecten kan sorteren afhankelijk van het type 
receptor waaraan het bindt. Daarnaast is het zo dat chemokinen ook 
verschillende effecten kunnen sorteren afhankelijk van de fysiologische 
omstandigheden en dat er een bepaalde mate van synergie tussen 
chemokinen bestaat. Bovendien kan de structuur van een chemokine 
veranderen en daarmee ook het biologische effect. Door dit alles kan het 
effect van chemokinen en van chemokine-receptoren verschillen per celtype, 
lokalisatie en fase van ontstekingsreactie. Van CCR5 wordt bijvoorbeeld 
aangenomen dat dit van groter belang is in de latere stadia van plaque 
ontwikkeling dan in eerdere stadia.  
Naast bovengenoemde overwegingen betreffende de werkzaamheid moet 
natuurlijk ook rekening gehouden worden met eventueel nadelige effecten 
van interventie in het chemokine systeem. Omdat chemokinen en 
chemokine-receptoren een onderdeel vormen van het immuunsysteem zou 
blokkering ervan een verhoogde kans op infecties kunnen geven. Het is 
bijvoorbeeld bekend dat aanwezigheid van CCR5∆32 genetische variant de 
kans op infectie met het 'West Nile virus' verhoogt en ook de kans op het 
krijgen van een bepaalde vorm van encephalitis. Als laatste moeten ook 
tolerantie en veiligheidsaspecten meegenomen worden die gerelateerd zijn 
aan het langdurig gebruik van geneesmiddelen die worden ingezet bij 
chronische ziekten zoals hart- en vaatziekten. Om de kosten-baten-ratio 
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gunstig te laten uitvallen verdient het aanbeveling om te zoeken naar 
patiëntengroepen die het meeste baat zouden kunnen hebben bij een 
dergelijke therapie; een en ander vraagt dus om therapie op maat.  
 
Zoals uit dit proefschrift blijkt kunnen genetische associatiestudies helpen bij 
het uiteindelijk ontwikkelen van therapie op maat. Dergelijke studies kunnen 
worden gebruikt om pathofysiologische mechanismen op het spoor te 
komen, kunnen een indicatie geven van mogelijk te verwachten effecten bij 
medicamenteuze interventie en kunnen helpen om die patiënten te 
identificeren die speciaal baat hebben bij een betreffende therapie. Tevens 
kan uit dit proefschrift geconcludeerd worden dat het chronische 
ontstekingsproces dat leidt tot vaatschade en meer specifiek de centrale rol 
die chemokinen en chemokine-receptoren hierin spelen vanuit zowel 
pathofysiologisch als therapeutisch oogpunt een veel belovend terrein van 
onderzoek is bij patiënten met hart- en vaatziekten, speciaal bij patiënten 
met eindstadium nierfalen en bij patiënten met diabetes mellitus type 2 die 
ondanks de huidige therapieën een hoog risico lopen om aan hart- en 
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